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ABSTRACT

Tayyari, Fariba. Ph.D., Purdue University, December 2013. Development of Isotags for
NMR Based Metabolite Profiling and Applications. Major Professor: Daniel Raftery.

NMR spectroscopy is a powerful analytical tool for both qualitative and
quantitative metabolite profiling analysis. However, accurate quantitative analysis of
biological systems especially using one-dimensional NMR has been challenging due to
signal overlap. In contrast, the enhanced resolution and sensitivity offered by
chemoselective isotope tags have enabled new and enhanced methods for detecting
hundreds of quantifiable metabolites in biofluids using NMR spectroscopy or mass
spectrometry. In this thesis we show improved sensitivity and resolution of NMR
experiments imparted by 15N and 13C isotope tagging which enables the accurate analysis
of plasma metabolites.
To date, isotope tagging has been used in conjunction with a single analytical
platform. The inability to detect the same metabolites using the complementary analytical
techniques of NMR and mass spectrometry has hindered the correlation of data derived
from the two powerful platforms for applications such as biomarker discovery or the
identification of unknown metabolites. To address this problem, we describe a smart
isotope tag, 15N-cholamine, which possesses two important properties: an NMR sensitive
isotope, and a permanent charge for MS sensitivity. Finally, we present a study on

xvii
metabolite profiling using intact breast cancer tissue samples in which we exploit the
combined strength of NMR and multivariate statistical methods for metabolite profiling.

1

CHAPTER 1. INTRODUCTION TO METABOLITE PROFILING

1.1 Introduction
Metabolomics or metabolite profiling describes the advanced study of metabolism
in biological systems. In one sense, metabolite profiling has been used for decades for
human disease diagnosis,1 and the initial studies were actually introduced in early 1970s.2
However, the instrumentation available at that time made definitive studies very
challenging. The term “Metabonomics” was introduced 28 years later by Nicholson et al.
as “the quantitative measurement of the dynamic multiparametric metabolic response of
living systems to pathophysiological stimuli or genetic modification”,3 and represented a
re-birth of the field in some sense.

Metabolomics has also been described as “a

comprehensive and quantitative analysis of all metabolites” in biological systems and the
"systematic study of the unique chemical fingerprints that specific cellular processes
leave behind".4,5 Scientists are often used these terms interchangeably. The Metabolome
was first introduced by Oliver et al. in 1998 as the complete set of metabolites
synthesized by an organism.6
Metabolites represent the downstream products of genes and proteins and as such
they integrate the biological information and changes to that system that occur over time.
Metabolites are not only building blocks of many other biological components such as
proteins, they also have many other important roles in biological systems such as
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signaling, enzymes activity, and providing energy (ATP). The metabolome is dynamic,
and the level of metabolites in a biological system respond sensitively to a variety of
changes, including influences by drugs, disease or any other stress caused by a cell’s
environment at a certain time.
Given the sensitivity to cellular perturbations, metabolite profiling can be used to
study a variety of biological questions, including the differences between groups such as
disease and healthy at a molecular level and convey extensive information to the field of
“molecular epidemiology.” Metabolomics has some advantages over other ‘omics such as
genomics and proteomics. First metabolite profiling provides detailed information related
on phenotype, while genomics and to a lesser extent the proteome provide more
information about genotype.7 Second, the number of metabolites represented in the
human metabolome is significantly less than the large number of genes and proteins in
the human genome or proteome, which makes metabolomics more discriminating.8,9
Also, since a given metabolite is same in different organisms, more generic techniques
can be used for metabolomics and extended across species.8 Lastly, the technology
involved in measuring metabolomics is faster and less expensive than for genomics or
proteomics.8
In this chapter, the entire workflow of metabolite profiling, as illustrated in Figure
1.1, will be reviewed with a focus on human samples.

1.2 Biological Samples and Sample Preparation
Metabolomics approaches can be applied to a variety of different biological
matrices, including biofluids, tissues, and cells. It is critical to choose an appropriate
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preparation method, including all the steps from the time the sample is collected until the
data acquisition is started. The method has to be reliable and reproducible, and based on
the type of the sample and technique to be used for analysis.
Since the metabolome is dynamic, quenching of the metabolism is necessary,
such as using cold methanol, trifluoroacetic acid, or even freezing with liquid nitrogen,
followed by appropriate storage at cold temperatures. Other preparation steps are
dependent on the analytical technique to be used and the type of the sample or organism
of interest. These steps include extraction, separation, isolation, purification,
derivatization, buffer addition, and etc.

1.2.1 Samples
Metabolite profiling studies have been reported on many different biological
systems such as cells, tissues and a number of biofluids including plasma, serum, urine,
bile, cerebrospinal fluid, seminal fluid, amniotic fluid, synovial fluid, and saliva.1018

Among all the samples serum, plasma and urine have been most often targeted for

metabolomics studies because the sample is non-invasively collected and thus easily
obtained.

1.2.1.1 Blood Samples
Blood is the most readily accessible biofluid and has been subjected to many
metabolomics studies since it is rich in metabolites and potentially provides vital
information on almost every type of cell. In a living organism blood serum or plasma
provides a direct global view of the metabolic status. Blood has two parts, a cellular
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component including red and white blood cells and plasma, a liquid carrier in which these
cells and other molecular species are suspended.

19

Differences between plasma and

serum occur from the way they are prepared from blood. Plasma is obtained by adding
anti-coagulants to the blood sample; then by centrifuging the mixture, the cellular portion
is precipitated and the plasma supernatant is obtained. However, to obtain serum the
blood is allowed to clot without adding any anti-coagulant. Plasma is more viscose
compare to serum because the clotting proteins remain in the supernatant.20 While serum
and plasma have very similar metabolite profiles; however, differences in the
distributions of specific metabolites and even the number of metabolites in each fluid has
been reported.21 Soluble proteins still remain in both plasma and serum, and depending
on the analytical technique used, additional preparation steps are required for further
purification or deproteination.

1.2.1.2 Urine Samples
Ease and non-invasive sampling of urine add to the other advantages of urine
including a relatively high concentration of metabolites and low concentration of
proteins, which make urine a favorable target for metabolomics studies. However, urine
suffers from high salt content that triggers problems in some analytical methods.
A number of confounding factors can cause differences in the concentrations of
urine metabolites between individuals, including the volume of urine, amount of the
water and physiological conditions such as age, gender, weight, personal diet and
environmental effects.22 Urinary metabolites also have different concentrations over time
for a single individual since they reflect the conditions that have been introduced to the

5
body such as food intake, medication, and exercise. Nevertheless, the urinary metabolite
profile can provide an immense amount of information on biological status.
Urine sample preparation usually is minimal and can be performed after the
sample is collected. However, if the urine samples need to be stored, they can be at or
below −25 °C without preservatives. If sterility is difficult to maintain or unachievable,
and for the case of temporary storage at 4 °C, the addition of preservatives is necessary.
In these situations 0.1% sodium azide, is preferred over preservation with sodium
fluoride. 22

1.2.1.3 Tissue Samples
Tissue samples have been used for metabolite profiling for a number of years.23-24
However, metabolic profiling of intact tissue has become of increasing interest,25-27 as
the study of intact tissues can help researchers better understand the molecular basis of
diseases.25,28 Tissue extraction methods, such as using methanol/water/chloroform
destruct the cell structure, and pull out the metabolites into either the aqueous or organic
layer, depending on their solubility. Typically these two solutions are analyzed
separately. In contrast, the analysis of intact tissue samples is non-destructive and
preparation is fast and minimal (addition of deuterated water, buffer, etc.). In addition to
the other advantages of using intact tissues, these samples can be used later for clinical
studies.
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1.2.1.4 Cell ad Cell Medium Samples
Metabolite profiling of cells have been used to discriminate between different
type of tumors and cell lines.29,30 Cell samples also provide valuable information for
studying biochemical pathways and mechanisms. Numerous studies has been conducted
on different types of cancer cells and they show diverse biochemical pathways.31,32 To
quench cell metabolism, liquid nitrogen or cold methanol are the most common
methods.33,34 Cell sample preparation should be prudently done to save the integrity of the
sample and to limit leakage of intracellular metabolites, especially for the types of cells
that are highly sensitive to osmotic changes of medium.34,35 Metabolite profiling of cell
culture medium are not as common as cells. It can be used to evaluate the impact of the
medium on the cell culture performance.36

1.2.2 Sample Preparation for NMR Experiments
One of the main advantages of NMR over mass spectrometry is the ease of
sample preparation. Except for experiments that require samples to be derivatized,
sample preparation for NMR experiments is minimal. Blood samples including plasma
and serum contain proteins and lipids which cause broad lines in the NMR spectrum. To
detect small molecules several spectral editing methods are available and widely used.
Only in some cases are samples deproteinized prior adding them into NMR tubes. Urine
samples benefit from their low concentrations of proteins and high concentrations of lowmolecular-weight compounds; therefore sample preparation is minimized. Tissue
preparation methods depend on the type of experiment performed, which group of
metabolites are of interest, and the instrumentation used: liquid state NMR, HR-MAS,
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solid state NMR, etc.25,37,38 Overall, and especially beyond NMR analysis, extraction has
been the most common method for tissue sample preparation. Among the extraction
methods solid-liquid extraction is more common. In this method a solvent, typically
deuterated water, is added to the solid material, followed by shaking, vortexing or stirring
to enhance the contact between them. For HR-MAS, intact tissues are used and only
deuterated water or buffer, with or without reference, is added. Different protocols are
available for quenching cell metabolism and perform cell lysis.

1.3 NMR Spectroscopy for Metabolomics Applications
Among the techniques used for metabolomics studies, NMR and Mass
spectrometry (MS) are the two most common.39 Both techniques have advantages and
disadvantages, and i general they are complementary to each other. NMR is highly
selective, non-destructive, requires minimal sample preparation, is robust, and the data
generated by NMR are very quantitative and reproducible. However, NMR is costly,
suffers from poor sensitivity, and the complex spectra typically show a high degree of
spectral peak overlap. Later in this chapter and thesis, some the methods to enhance
sensitivity and resolution will be discussed.

1.3.1 Water Signal Suppression
Water comprise abundantly in most of the biological samples. In NMR-based
metabolomics studies overwhelming signal of the water resonance is the obstacle.
Without water suppression, water gives rise to a large residual signal and attenuate or
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eliminate metabolites signals. Therefore, it is very common and desirable in NMR
metabolomics studies to suppress the water resonance signal.
The water resonances can be suppressed by the use of appropriate standard NMR
solvent suppression methods. Several pulse sequences exist for this purpose Including,
Presaturation (PRESAT), water suppression enhanced through T1effects (WET)
sequence, WATER suppression by GrAdient Tailored Excitation (WATERGATE),
presaturation utilizing relaxation gradients and echoes (PURGE), and excitation
sculpting, etc.40-44
Among these pulse sequences presaturation technique is more commonly used in
metabolomics studies. The pulse sequence consists of two pulses, first a selective pulse to
saturate water frequency (~ 4.8 ppm), it is a continuous low-power radio frequency pulse
over the few second time period of an acquisition delay, usually 1-2 sec. Second one is a
non-selective high power 90º pulse to excite other protons except saturated water
protons.41 In a spectrum generated by this pulse sequence water signal is still exist,
because of the water portion that is not perfectly irradiated, although it is highly
suppressed.

1.3.2 1D NMR Spectroscopy Pulse Sequences Used for Metabolomics
In metabolomics studies it is important to select a proper NMR acquisitions are
from available NMR experiments, including 1D NOESY with water suppression, CPMG
1D 1H with water suppression, 1D selective TOCSY, DOSY, etc. These methods have
advantages and disadvantages, therefore selection of a method depends on the origin of
the sample and metabolite molecular groups of interest.
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1.3.2.1 1D NOESY
1D NOESY (nuclear Overhauser enhancement spectroscopy) is one of the most
commonly used pulse sequences in metabolomics. 1D NOESY is usually coupled with
PRESAT to attenuate the water peak and called NOESYPRESAT.45 In this sequence the
water resonance is irradiated two times, first during relaxation delay, RD, (1-3 sec.), and
again during the mixing time, tm, (100-150 msec.).45 With this method, the water signal in
biofluid samples is attenuated by a factor of 105 or more. The spectra acquired by
NOESY show broad signals from macromolecules such as proteins and lipids in addition
to the narrow spectral features from small molecules. Therefore, the 1D NOESY
sequence is more suitable for urine than serum or plasma samples, since urine contains a
low concentration of proteins.

1.3.2.2 1D CMPG
Blood samples including plasma and serum, cells and tissue all contain
macromolecules, which display broad lines in the NMR spectrum due to their slow
tumbling rates that limit spectral averaging. Therefore, a more suitable pulse sequence for
the analysis of these samples should be able to suppress the broad signals resulting from
macromolecules. The most common sequence used to suppress macromolecular signals is
the CPMG (Carr-Purcell-Meiboom-Gill) spin echo pulse.46 In this sequence there is a 90°
phase shift between the 90° initial pulse along the x-axis and the following 180° pulses
along the y-axis. This phase shift creates echoes that all form along y-axis and eliminate
most errors of the 180° pulses. Fourier transformation of the CPMG free induction decay
produces high resolution NMR spectra, which are highly reproducible and quantitative.
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Much like the NOSEY sequence, most of the time CPMG is coupled with PRESAT, and
is known as PRESAT-CPMG.

1.3.2.3 1D Selective TOCSY
1D NMR spectra of biological samples are crowded and highly congested;
therefore some of the smaller signals are overlapped or buried under other, larger signals.
Selective total correlation spectroscopy (Selective-TOCSY) is a NMR experiment that
can be used to identify distinct spin-systems, i.e., a group of spins from the sample
molecule which are connected by J-couplings.47 During the TOCSY evolution period, the
NMR magnetization spreads from one 1H spin to the rest of members of the spin system
via J-coupling, eventually throughout the molecule. Selective TOCSY, in which a single
peak is excited and the coupled spins are revealed in the spectrum, has been used in
biological samples and showed promising results.48,49 This technique can help to detect
and quantify metabolites with concentrations 10–100 times below those of the major
components.48

1.3.3 2D NMR Spectroscopy Pulse Sequences Used for Metabolomics
1D 1H NMR spectra are often complicated because of the overlapping signals due
to the large number of metabolites in biological samples.50 2D NMR experiments are
sometimes able to improve the resolution by dispersion signals in two different
dimensions. Several 2D NMR experiments are used in metabolomics studies, including
heteronuclear single quantum coherence spectroscopy (HSQC) and heteronuclear
multiple bond correlation spectroscopy (HMBC), 2D J-resolved spectroscopy, correlation
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spectroscopy (COSY), total correlation spectroscopy (TOCSY), etc. However, the
disadvantages of 2D NMR experiments, including longer acquisition times, larger data
size and difficult data analysis compared to 1D NMR decrease their use and interest for
metabolomics studies.51 2D-HSQC is the only 2D NMR experiment used for the work in
this thesis, and therefore only the 2D-HSQC experiment is discussed in this chapter.

1.3.3.1 2D HSQC
HSQC displays correlations between heteronuclear spins across a single chemical
bond, and thus allows the identification of the directly connected nuclei.52 Usually, the
detected correlation is between 1H and either 15N or 13C nuclei. For instance, 2D 1H–15N
HSQC NMR correlates 1H and

15

N NMR resonances from the same molecule, and as a

result only those nitrogen nuclei that are coupled to protons are visible in the
spectrum.53,54 Several studies have been done for identification and quantification of
metabolites by tagging them with 15N or 13C and using HSQC NMR experiments.55-57

1.3.4 Enhancement in Sensitivity and Resolution
Over the past 10 years a number of improvements in NMR instrumentation have
provided significant gains in performance, both in resolution and sensitivity. Higher
resolution and sensitivity are greatly improved by the use of higher magnetic field
strengths,41 and higher magnetic fields such as 18.8 Tesla (800 MHz for 1H NMR) or
above are attractive for metabolomics studies.58,59 In addition, cryogenic (cryo) probes
can significantly increase the signal-to-noise ratio (SNR) by reducing the level of thermal
noise in the detection coil circuit. By cooling the probe and its electronics from room
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temperature to 20 K, the SNR improves almost four fold. One of the disadvantages of
NMR compared to MS in metabolomics studies is the amount of sample required. Microcoil probes can be used to reduce the amount of sample required for NMR studies and
thus limit this problem. Various micro-coil probes have been designed and constructed
for metabolomics studies.60-62 Coupling the NMR instrument with liquid chromatography
is another way to increase the resolution, while a combined LC-MS-NMR approach can
assist the identification of unknown metabolites. In this approach LC fractions are split
between MS and NMR instruments for parallel analysis.63
Quantifying and identifying metabolites are some of the most important and
challenging aspects of metabolite profiling, and therefore methods that improve NMR
resolution and sensitivity are of great interest. Since biological samples are rich in
metabolites, conventional 1D NMR methods suffer from the often overwhelming overlap
of metabolite signals. In many cases, low concentrated metabolites are not even detected
since they are buried under the other, larger signals. The relatively small dispersion of the
1

H NMR chemical shifts and the large number of spin-spin couplings between

metabolites are the main causes of signal overlap. One of the strategies that has been
demonstrated to improve NMR chemical shift dispersion is to detect heteronuclei such as
15

N,

13

C. 13C and

15

N spectra are simpler, as they have fewer couplings; however, these

nuclei have low natural abundances, and therefore conventional methods to detect these
nuclei suffer from low sensitivity.
In contrast, isotope labeling can enhance the sensitivity. Isotope labeling has been
performed in vivo and in vitro in biological systems. In vivo isotope labeling has been
accomplished by feeding animals with

13

C-enriched diets,64 as well as numerous cell

13
studies that use

13

C labeled glucose,65 for example, to provide detailed mechanistic

information. In vitro isotope labeling studies are often easier to perform and focus on
improving the measurement technology to differentiate biological samples. One attractive
approach involves the labeling specific classes of metabolites in biofluids with
15

13

C and

N, which has been performed with promising results.66,55-57 For example, an isotope-

labeled acetylation reaction using

13

C-acetic anhydride can label the amines present in

samples, and later the tagged metabolites are detected using 1H-13C 2D HSQC.66 Amino
acids and carboxylic acids can labeled with

15

N-ethanolamine, and the amide can be

detected by 1H-15N 2D HSQC.55 This approach showed an improvement in the limit of
detection such that over 100 metabolites in human urine and serum could be be detected.

1.4 Data Processing and Statistics

1.4.1. Pre- Data Processing
NMR spectral data processing is a critical step in metabolomics profiling and
should be done with care. However, before data processing to be subjected to
multivariate and/or univariate analyses, it has to be preprocessed. Accurate results cannot
be achieved without appropriate preprocessing.
Preprocess steps after NMR data acquisition depend on the study and NMR
experiment, but typically include phase and baselines correction, peaks alignment,
bucketing (binning) or peak integration, normalization, and scaling.67-68 These steps help
eliminate or decrease the undesired spectral variations over samples.
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1.4.1.1 Phasing and Baseline Correction
Phase and baseline corrections are the first steps in preprocessing following data
acquisition. Baseline distortions can be corrected by automated baseline correction or
manually, using a variety of processing software packages such as Topspin (Bruker
Biospin, Billerica, MA), VnmrJ (Varian, Palo Alto, CA), MestReNova (Mestrelab
Research, Santiago deCompostela, Spain), and KnowItAll (Bio-Rad Laboratories,
Hercules, CA).

1.4.1.2 Peak Alignment and Bucketing
Small chemical shift changes can be caused by different factors, including
instrumental effects (see below), changes in sample pH or ion concentrations, or the
presence of other metabolites or macromolecules. It should be noted that the chemical
shift changes caused by these factors do not affect all chemical shifts for all metabolites
at the same level. Chemical shift offsets caused by the NMR instrument can be fixed and
aligned by using a reference signal such as DSS (4,4-dimethyl-4-silapentane-1-sulfonic
acid), TSP (trimethylsilyl propionate) at 0.00 ppm or a peak from one of the metabolites.
For example some metabolomics studies use the methyl doublet peaks of alanine around
1.48 ppm as a reference.69-71 Peak alignment can be performed manually or by using
special algorithms such as RSPA (recursive segment-wise peak alignment).72 Usually, the
next step following the peak alignment is either bucketing or peak integration. For
bucketing, the NMR spectrum is divided into a set of desired spectral width segments (a
typical width is 0.04 ppm), which are known as a bucket or bin. Bucketing integrates the
peak areas over that spectral segment, and ensures a consistent measurement of the same
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resonance for all samples by reducing the effect of pH variations or ion concentrations on
chemical shifts.73 A data matrix is produced by bucket segments, can be saved into a text
file or exported to a worksheet directly to be used further data analysis. Data sets that use
bucketed spectra are easier to work with, as they typically have only about 250 – 400
buckets per spectrum. An alternative to bucketing is the direct integration of spectral
peaks. Although this is more time consuming, it can be more accurate and used to derive
absolute concentrations of specific metabolites. Typically, though, the number of
integrated metabolites is less, ranging from 20-40 for serum or tissue samples and up to
about 80 metabolites for urine.

1.4.1.3 Normalization and Scaling
Metabolomics data typically have to be normalized, otherwise the samples may
not be comparable to each other. For the normalization process different approaches can
be used.68,74 A common method for normalization is integral normalization known also as
constant sum normalization. This approach normalizes each spectrum to a constant total
integrated intensity across the whole region. Another method uses a standard with a
known concentration that is to each sample; normalization of the spectrum is based on the
standard.73 For tissue samples, the data can be normalized with respect to the weight of
the tissue.68
Metabolites in biological samples have a wide range of concentrations. The
absolute variation in metabolite levels is related to their concentrations.68 Scaling is
therefore used to avoid the selection of only high concentration metabolites as biomarker
candidates because they tend to exhibit high variations. Scaling therefore helps to
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emphasize lower concentration species that might otherwise be overlooked. A number of
scaling methods are available to use such as Pareto scaling, variance scaling, Log scaling,
range scaling, vast scaling, and level scaling.67,68,75,76

1.4.2 Statistical Methods
Two general approaches are used to perform statistical analysis on the rich
metabolomics NMR data, exploratory analysis and confirmatory analysis. Exploratory
data analysis is used to find patterns in the data set using methods such as principal
component analysis (PCA) and hierarchical clustering analysis (HCA). However,
confirmatory data analysis makes an implicit use of the group labels. Methods for
confirmatory analysis include the univariate Student’s t-test, and multivariate methods
that include partial least square-discriminant analysis (PLS-DA), orthogonal signal
correction-PLS-DA (O-PLS-DA), logistic regression and many others.77

1.4.2.1 Unsupervised Methods
The exploratory methods commonly used in metabolomics are known as
“unsupervised” since patterns are discovered without assigning the spectra to classes such
as “disease” or “healthy.” This approach draws distinctions between groups of samples
with respect to their chemical compositions, i.e., metabolite concentration level changes
among the samples. The most commonly used multivariate method in metabolomics is
PCA.78-83 PCA transforms the multidimensional data and builds linear multivariate
models. The PCA model is built on the basis of orthogonal vectors (Eigenvectors). The
principal components (PCs), are the eigenvectors of X, PCs are initially calculated from
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the original data set X by a diagonalization of the covariance data matrix. The PCs are
then ranked by their eigenvalues in decreasing order. The first PC (PC1) thus describes
the direction of the largest variations generated across the set of spectra, the second PC
(PC2) then describes the direction for the largest portion of the remaining variation, and
similarly for the rest of the PCs. Except for the first several PCs, the other remaining PCs
mostly contain noise. Therefore, the first few PCs are typically used to display the
variation in a “score plot.” Separation of samples along a particular PC is explained
using the loading plot; it shows the contribution of each variable in the original data to a
principle component. Loading plot assists with the identification of potential biomarkers.

1.4.2.2 Supervised Methods
Popular confirmatory methods include partial least square discriminant analysis
(PLS-DA), orthogonal signal correction partial least square discriminant analysis (OPLS-DA), t-test, logistic regression, k-nearest neighbor (KNN), and soft independent
modeling by class analogy (SIMCA). The class information for each sample is assigned
prior to the analysis, and therefore these methods are known as supervised analysis.
PLS is one of the most common used supervised methods. PLS fits the data
matrix of predictors X and class matrix or vector of responses Y, and find a linear
regression model to the new coordinate system. Equation 1.1 shows the general equation
for the linear regression model. Y is the predicted outcome value for the linear
regression model with the b, regression coefficients, 1 to z; b0 is the Y intercept while the
values for the X, predictor variables, are 1to z.
Y = bo + b1X1 + b2X2 +…+bzXz

(eq. 1.1)

18
Each orthogonal axis in PLS is named a latent variable (LV). PLS-DA is the
combination of PLS and discriminant analysis (DA), where DA is a statistical method for
determination of a linear combination of features to predict to which class a case (or
sample) belongs.84,85 PLS-DA modeling can be used to find the difference between preassigned sample groups and recognize variables responsible for the class separation.
Qualitative values including class or category of samples are included in Y matrix.
Typically, Y is set up as a “dummy matrix” where, for example, Disease = 1 and
Healthy = 0. The PLS-DA method in particular, and most supervised methods in general,
suffer from data over-fitting, therefore it is crucial to perform the result validation
otherwise.86 Cross validation is the most common method for validation, in which results
are applied to a new set of observations that was not used to build the model.87 Leaveone-out cross-validation (LOOCV) is one of the most commonly used validation methods
for PLS-DA models in metabolomics studies.88-90 In this technique one single observation
from the original sample set is used to evaluate the predictive accuracy of the model,
while all the other samples are used as the training data to build the model. Each sample
is used once as the validation data in the cross validation process.

1.4.2.3 Univariate Analysis
Univariate methods are often employed to identify significant metabolites that are
altered between different groups. To identify significant difference, P-values, calculated
from the Student’s t-test, Welch’s t-test, Mann-Whitney U test, or other variants are used
to explains the probability of two means, are used.91 Values less than 0.05 are generally
considered statistically significant. However, the analysis of multiple metabolites results
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in a process of making multiple comparisons between the sample classes, which often
leads to an overly optimistic set of significant metabolites, of which many may be false
discoveries. A number of methods are used to try to correct for this effect and generally
involve the calculation of False Discovery Rate.92-95
Box-and-whisker plots (box plots) are a descriptive statistic for illustrating groups
of numerical data. Box plots show differences between populations with no assumptions
regarding the statistical distribution. Figure 2 illustrates a single box plot in some detail.
The receiver operating characteristic (ROC) curve describes the function of a variable in
binary classification. In binary classification tests, sensitivity and specificity are the key
statistical measurments.85,96,97 Several additional terms are useful for defining sensitivity
and specificity, including the true positive (TP), true negative (TN), false negative (FN),
and false positive (FP) rates. If a disease is proven in a patient, and diagnostic test also
indicates the disease, the result from test is considered a true positive (TP). Similarly, if
the diagnostic test shows the patient does not have a disease and also proven that the
person does not have it, the result of the test is a true negative (TN). If the diagnostic test
indicates the disease in a person who does not actually have the disease, the result is a
false positive (FP). And the result is a false negative (FN) if a disease is proven in a
patient but the result of the diagnostic test indicates no disease. Equations 1.2, 1.3, and
1.4 describe sensitivity, specificity, and accuracy, respectively base on the terms of TP,
TN, FP, and FN.94

20
Sensitivity = TP/(TP + FN)

(eq. 1.2)

Specificity = TN/(TN + FP)

(eq. 1.3)

Accuracy = (TN + TP)/(TN+TP+FN+FP)

(eq. 1.4)

The area under the ROC curve (AUC), measurement describes the overall
accuracy of a test. An AUC of 0.5 describes equal distribution between two groups, i.e., a
random result equivalent to flipping a coin, and the test based on it is valueless for
discrimination. An AUC of more than 0.9 is considered to be an excellent test, and more
than 0.8 considered good.98

1.5 Thesis Summery
The rest of this thesis focuses on the development of new methods and
applications in NMR-based metabolomics. In Chapter 2, derivatization approaches were
used for quantitative analysis of human blood plasma.

Improved sensitivity and

resolution of NMR experiments imparted by 15N and13C isotopes enhanced the metabolite
detection pool and accuracy of plasma metabolite analysis. Furthermore the approach can
be extended to many additional metabolites in almost any biological mixture for high
throughput analysis. A new “smart isotope tag,”
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N-cholamine, which possesses two

important properties: an NMR sensitive isotope, and a permanent charge for MS
sensitivity, is discussed in Chapter 3. This unique approach enables effective detection of
the carboxyl-containing metabolome by both analytical methods. In Chapter 4, HR-MAS
was used in a metabolomics study to identify altered concentrations of small-molecule
metabolites in triple negative breast cancer (TNBC). In this chapter the metabolite
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profiles of African Americans and Caucasians were studied and compared. It is shown
that NMR-based metabolomics has good potential for identifying altered metabolism in
the aggressive TNBC that is observed especially in African American women.
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CHAPTER 2. QUANTITATIVE ANALYSIS OF BLOOD PLASMA METABOLITES
USING ISOTOPE ENHANCED NMR METHODS

2.1 Introduction
Nuclear magnetic resonance (NMR) spectroscopy is increasingly used in
metabolomics for the analyses of multiple metabolites in biofluids and tissue.
Metabolomics promises a number of important applications in biomedicine including a
more detailed understanding of biological processes, the discovery of the biomarkers
associated with numerous diseases, pharmaceutical development and toxicology.1-6 It is
increasingly recognized that NMR is a very attractive methodology for quantitative
metabolomics because of its high reproducibility and quantitative nature. In particular,
the improved resolution of two-dimensional (2D) NMR methods is considered very
useful for metabolomics applications7-11. However, a major drawback of 2D NMR is that
the cross-peak volume in the spectrum is influenced by numerous experimental or
intrinsic parameters including the non-uniform excitation profile of the radio frequency
pulses, number and duration of the pulses, inter- pulse delays, relaxation times and the
magnitude of indirect spin-spin couplings. The high sensitivity of peak intensities (or
volumes) to these parameters has limited the use of 2D (particularly 1H homonuclear 2D)
experiments for quantitative analysis in metabolomics.
To overcome the limitations of quantitation and to improve the analysis, new
higher resolution 2D approaches utilizing 1H-13C heteronuclear 2D experiments (HSQC)
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have been proposed.12,13 One approach is to utilize the information from 2D 1H-13C NMR
spectra of standard compounds obtained under identical conditions and relate the peak
heights in the samples to standard mixtures12; another is to utilize calibration curves
obtained using 1H-13C HSQC spectra for individual metabolites to determine the
metabolite concentrations.13 Most recently, a more general approach that does not require
measurements of standard compounds was proposed.14 This method utilizes correction
factors derived theoretically from the solution of the Bloch equations and the analysis of
product operator formalism incorporating longitudinal (T1) and transverse (T2) relaxation
parameters, 1H-13C heteronuclear J-coupling and various delays used in the pulse
sequence.
A major drawback of using the 1H-13C HSQC experiment for quantitative
analysis, is the lack of sensitivity arising from low metabolite concentration and natural
abundance of

13

C (1.1 % natural abundance). To compensate this limitation, unusually

long acquisition times (nearly 10 hrs or more) are typically required since the NMR
sensitivity scales with the square-root of the number of scans. Moreover, although 1H-13C
HSQC greatly enhances resolution when compared with 1D NMR, given the complexity
of the biological samples, the resolution obtainable from a single 2D experiment is not
always adequate for analyzing a large number of metabolites.
In the present study, with the goal of circumventing the current drawbacks of
limited resolution and sensitivity, we utilize a combination of isotope tagging approaches
and 2D NMR methods to accurately analyze human plasma metabolites. A number of the
most common metabolites in blood plasma were quantified using this approach after
validating the experimental protocols using a mixture of synthetic compounds.
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Metabolites containing carboxyl and amino groups were tagged with

15

N or

13

C,

respectively, before detection by 2D NMR. We have recently shown the proof-ofprinciple approaches to introduce isotope tags using simple chemical derivatization
methods and that the NMR spectra of the tagged metabolites improve both resolution and
15-18

sensitivity.

The combination of advanced isotope tagging methods with conventional

1D and 2D NMR methods as described in the present study enables the quantitative
analysis of a large number of metabolites in human blood on a routine basis.

2.2 Materials and Methods

2.2.1 Chemicals and Samples
Twenty-eight metabolite standards (Table 2.1), 4,4-dimethyl-4-silapentane-1sulfonic acid (DSS), maleic acid, ethanolamine (all from Sigma–Aldrich, St. Louis, MO),
4-(4,6- dimethoxy [1,3,5] triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM)
(Acros, Geel, Belgium),

15

N-ethanolamine,

13

C-formic acid (Cambridge Isotope

Laboratories, Andover, MA), N, N-dicyclohexylcarbodiimide and N-hydroxysuccinimide
(Sigma-Aldrich) were used without further purification. An ultra-pure primary
quantitative standard, tris(hydroxymethyl)aminomethane, (99.9%) was obtained from
Mallinckrodt Baker Inc. Phillipsburg, NJ. Human blood plasma (10 × 1 mL) was
procured from the National Institute of Standards and Technology (NIST, Gaithersburg,
MD). Frozen plasma samples were transported to Purdue under dry ice and stored at
−80 °C until used for the analysis.
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2.2.2 Calibration of the Standard Solutions
Twenty-eight metabolites that commonly occur in human blood plasma were
19

selected based on entries in the human metabolite database (HMDB),

the analysis of

isotope labeled 1H-13C HSQC and 1H-15N HSQC spectra, as well as 1D and 2D 1H-1H
TOCSY spectra of a human plasma sample. Stock solutions (20 mM) for the synthetic
analogues of all these 28 metabolites (Table 2.2) and internal standards, DSS (5 mM),
maleic acid (20 mM) and ethanolamine (20 mM), were prepared. The concentration of
the DSS solution was calibrated using 1H NMR against a primary stoichiometric
standard, tris(hydroxymethyl)aminomethane (22.4 mM), prepared in the lab. The
calibrated DSS solution was then used to calibrate all other standard solutions. Briefly,
solutions of the synthetic analogues of the 28 metabolites and internal standards were
divided into 5 groups as shown in Table 2.3. The grouping of samples in Table 2.3 was
such that the 1H NMR peaks for at least one proton from each compound in the group
were isolated for the measurement of the peak integral. For each group, the onedimensional (1D) 1H NMR spectrum was recorded, and based on the integrated area of
the isolated peaks with reference to DSS, exact concentrations of the standard solutions
were determined (Table 2.2).

2.2.3 Mixture Analyzing
A mixture of the 28 synthetic analogues of the metabolites was prepared using the
stock solutions such that the final concentration of each standard compound was matched
19

approximately to its expected concentration in human blood plasma (Table 2.1). From
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this mixture, three identical sets of samples (Set 1, Set 2 and Set 3) were prepared, Figure
2.1 shows a flow diagram illustrating the steps followed in the analysis of the standard
metabolite mixture using isotope enhanced NMR methods; each set consisted of four
solutions, 2× 500 μL and 2× 1000 μL of the mixture. All solutions were then dried under
vacuum. To the samples from Set 1, maleic acid solution (92 nmol) was added as an
internal reference and the solutions were diluted to 500 μL using doubly distilled water.
The carboxylic acid class of metabolites was then tagged with 15N-labeled ethanolamine
17

following the established procedure. To each sample from Set 2, ethanolamine solution
(200 nmol) was added as an internal reference and the solution diluted to 500 μL using
doubly distilled water. Amines and amino acids were subjected to
using a

13

13

C isotope tagging
18

C-formic acid reaction following the established procedure.

Finally, to the

samples from Set 3, DSS (9.44 nmol) was added as an internal reference and
reconstituted in 560 μL of phosphate buffer (pH=7.4) in D2O and transferred to 5 mm
NMR tubes for 1D and 1H-1H 2D TOCSY NMR experiments.

2.2.4 General Procedure for Tagging Metabolites

2.2.4.1 15N-Ethanolamine Tagging Procedure
3 μL 15N-ethanolamine (50 μmol) was added to the sample, the pH adjusted to 7.0
with 1 M HCl and DMT-MM (21 mg) was added to initiate the reaction.20,21 The mixture
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was continuously stirred at room temperature for 4 hrs to complete the reaction. The pH
was then adjusted to 5.0 by adding 1 M HCl or NaOH and the solutions were diluted to
600 μL by adding water or D2O prior to detection by 1H-15N 2D NMR.22,17

2.2.4.2 13C –formic Acid Tagging Procedure
13

2 μL of
mmol)

were

C-formic acid (0.05 mmol) and 5 mg of N-hydroxysuccinimide (0.04
dissolved

in

100

μL

tetrahydrofuran.

9

mg

of

N, N-dicyclohexylcarbodiimide (0.04 mmol) in 50 μL tetrahydrofuran was added to the
mixture and stirred at room temperature.23 After 15 min, the reaction mixture was
centrifuged
13

to

remove

insoluble

urea;

the

supernatant

containing

C-N-formyloxysuccinimide was then added to the mixture of synthetic analogues of the

metabolites along with 50 μL of 2 M NaHCO3 (0.1 mmol) aqueous solution. The reaction
was stirred at room temperature for 4 h and dried under vacuum. The residue was
redispersed in 500 μL D2O, the pH was adjusted to 7.0 by adding 1M HCl and then
transferred to a standard 5mm NMR tube for analysis using 1H-13C 2D NMR.18

2.2.5 Sample Prepration for NMR Experiments

2.2.5.1 Plasma Deproteination
Cold methanol (4° C; 9.6 mL) was added to 4.8 mL of the NIST plasma,
vortexed, and then kept for 30 min at -20 °C. The precipitated protein pellet was removed
after centrifuging at 13,200 g for 10 min. The supernatant was divided into 12 equal parts
and divided into three groups, each group consisting of four samples. Flow chart show in
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Figure 2.2 depicting the steps followed in the analysis of metabolites in the NIST plasma
sample using isotope enhanced NMR methods.

2.2.5.2 Isotope Tagging of Plasma Metabolites and Sample Preparation for NMR
In each group, two samples served as controls and the remaining two were spiked
with 400 μL of the stock solution mixture of 28 synthetic samples. All three groups of
samples were then dried in vacuum. One group was used to label metabolites containing
carboxylic acid groups with

15

N-ethanolamine, and the second group was used to label

metabolites containing amine groups with

13

C-formic acid, after the addition of internal

standards, either maleic acid or ethanolamine, appropriately. Identical procedures were
used for isotope tagging the plasma metabolites. To the third group of samples, DSS
(9.44 nmol) was added as an internal reference and reconstituted in 560 μL of phosphate
buffer (pH=7.4) in D2O. Samples from all the three preparations were transferred to 5
mm NMR tubes after adjusting the pH and solution conditions as described earlier for the
mixture of standards.
2.2.6 NMR Experiments
NMR experiments were performed at 298 K on a Bruker Avance-III-800
equipped with a room temperature 1H inverse detection Z-gradient probe or a Bruker
DRX-500 spectrometer equipped with a 1H inverse detection Z-gradient cryo-probe. 1D
NMR experiments for the five groups of standard samples (Table 2.3), the mixture of 28
synthetic analogues, and the plasma extracts were performed using a one pulse sequence
with residual water signal suppression by pre-saturation during relaxation delay. Thirtytwo scans with 64k time domain data points were collected with a sufficiently long
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recycle delay (20 s) to ensure complete recovery of the magnetization between scans. For
the

15

N isotope tagged samples, 1H -15N 2D HSQC experiments were performed
1

employing an INEPT transfer delay of 5.5 ms corresponding to a JNH of 90 Hz. Spectral
widths of approximately 10 kHz in 1H and 5 kHz in
800 MHz experiments. For

13

15

N dimensions were used for the

C isotope tagged samples, sensitivity-enhanced 1H-13C 2D

HSQC experiments were performed employing an INEPT transfer delay of 2.5 ms
1

corresponding to a JC-H of 200 Hz. Spectral widths of approximately 10 kHz for the 1H
dimension and 600 Hz for 13C were used at 800 MHz. For both 1H-15N HSQC and 1H-13C
HSQC 2D experiments, 128 free induction decays were collected along the indirect (t1)
dimensions using 4 transients per increment and 2s or 3s recycle delay, resulting in a total
acquisition time of 18 min for the 1H-15N HSQC and 28 min for the 1H-13C HSQC.
Phase-sensitive data were obtained using echo-anti-echo mode with nitrogen (for 1H-15N
HSQC) or carbon (for 1H-13C HSQC) decoupling during acquisition (t2 dimension) using
the GARP (Globally Optimized Alternating-phase Rectangular Pulses) sequence. 1H-1H
2D TOCSY experiments were performed for the neat (non-derivatized) samples with a
spectral width of 6 kHz (500 MHz) or 12 kHz (800 MHz) in both the dimensions. The
residual water signal was suppressed by presaturation. 400 free induction decays were
collected with t1 increments using 8 transients per increment and 2s recycle delay,
resulting in a total acquisition time of 116 min (500 MHz) or 111 min (800 MHz).
All 1D data were Fourier transformed with a 0.3 Hz line broadening function. The
2D data were zero-filled to 1,024 points in the t1 dimension after forward linear
prediction to 512 points and Fourier-transformed after multiplying by a squared sine-bell
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window function shifted typically by π/4 or π/2 along both the dimensions. All NMR data
were processed with Bruker Topspin 2.0 on a Redhat Linux platform and Bruker
XWINNMR 3.5 on a SGI / IRIX platform. An automatic baseline correction using a
polynomial of degree 5 was used to correct the baseline in both 1D and 2D spectra.
Peaks in the 1D and 2D NMR spectra were assigned to various metabolites based
17-19

on literature reports.

Integrals for well resolved peaks in 1D and 2D spectra were

obtained with respect to the peak for the internal standard DSS, maleic acid or
ethanolamine. Integral limits for each peak in the 2D spectra were selected such that the
selected region encompassed the whole peak and that no other peak interfered with the
selection. Once chosen for each type of 2D spectrum, the same sets of integral limits
were used for all other samples. Concentrations of the plasma metabolites were
determined by comparing the peak integrals from the spectra obtained with and without
spiking with the synthetic analogues, and also by directly comparing the peak integrals of
the plasma metabolites with those from the standards. The accuracy, reproducibility and
errors were estimated from two to eight measurements, depending on the detection of the
resolved peak for a particular metabolite in one or more types of spectra, for both
synthetic mixtures and plasma samples. The 1H-15N HSQC, 1H-13C HSQC and 1H-1H
TOCSY experiments and the data analyses were performed by independent persons.

2.3 Results
The standard solutions of the synthetic analogues of the plasma metabolites and
internal standards (maleic acid and ethanolamine), prepared based on their weights, were
calibrated using 1D 1H NMR. The actual concentration of the standard solutions prepared
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based on the weight varies depending on the purity and hygroscopic nature of the
compounds and hence, it is important to calibrate the standard solutions especially for
accurate quantitative analysis. The DSS solution, which was first calibrated using a
primary stoichiometric standard, tris(hydroxymethyl)aminomethane, was used for
calibrating all the standard solutions (Table 2.3). The difference between the
concentrations determined based on sample weight and calibration using 1D NMR varied
as much as 10% for all but three metabolites, which varied up to nearly 20% (Table 2.2)
due to hygroscopic nature of the metabolites or sample impurities.

2.3.1 Analysis of Synthetic Metabolite Mixture
A mixture of 28 metabolites was analyzed using both 15N and 13C isotope tagging
approaches. Fig. 2.3 shows 2D spectra of the mixture of 28 compounds with 15N and 13C
isotope tagging, as well as without tagging. The integrated 2D peak volumes were
obtained and then used to calculate the metabolite concentrations. Fig. 2.4 shows the
concentration of the compounds thus determined. As can be seen in the figure, an
excellent match between the metabolite concentrations derived from NMR methods and
the actual values was obtained. Further, as shown in Figure 2.5, a correlation of the NMR
derived values with the expected values showed a very good agreement for all low and
2

high concentration metabolites (R > 0.99).
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2.3.2 Quantitation of Plasma Metabolites
The 1D 1H NMR spectrum of the plasma sample obtained without isotope
labeling is highly complex, with only a relatively small number of metabolite signals
being isolated from other signals as shown in figure 2.6. 2D HSQC spectra of plasma
samples tagged with

15

N and

13

C isotopes provide resolved peaks for a much larger

number of carboxylic acid and amine containing metabolites. Fig. 2.7 shows 2D spectra
of the plasma obtained with and without 15N or 13C tagging. The 2D TOCSY spectrum of
the same plasma sample also provided a number of well resolved peaks (Fig. 2.7c).
However, unlike the HSQC spectra, the TOCSY spectrum showed a number of redundant
peaks for the same metabolite, which increases the complexity of the spectrum.
Quantitation of the plasma metabolites followed an identical procedure used for
the determination of the concentrations of metabolites in the synthetic mixture. The
integrated peak areas/volumes in the 1D/2D spectra of the neat and the spiked plasma
samples were obtained and the metabolite concentrations determined. Twenty-seven
metabolites that were identified in human plasma were analyzed in duplicate
measurements with and without

15

N and

13

C isotope tagging. Fig. 2.8 depicts the

concentration of the metabolites thus determined. The 1H, 13C and 15N chemical shifts for
the blood plasma metabolites analyzed in this study are shown in Table 2.4 and the
derived concentrations using a combination of four different NMR methods is shown in
Table 2.5. Further, the concentration of the carboxylic acid and amino metabolites were
also determined by directly comparing the 2D peak integrals with those for the
corresponding standard compound. Comparison of the metabolites concentration
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determined with and without spiking is shown in Fig. 2.8. Notably, the values determined
from both approaches agree well.

2.5 Discussion
1

H NMR spectroscopy is an attractive tool for the quantitative analysis of multiple

metabolites from intact biological samples. Considering its ease of use, reproducibility,
and high- throughput capabilities, 1D

1

H NMR spectroscopy is often used for

metabolomics-based studies. However, it is challenging to analyze the 1D NMR
spectrum of plasma for absolute quantitation as it contains a large number of overlapping
signals due to hundreds of metabolites present at variable concentrations. The multiplicity
of the signals due to J-coupling makes 1D 1H NMR spectra of plasma particularly
challenging. The interference from macromolecules such as proteins and lipids adds to
the complexity and causes baseline distortions in the spectra. Such overlap and baseline
issues substantially affect the accuracy of the quantitative analysis using 1D NMR. To
offset such limitations, a majority of the studies that use 1D NMR resort to comparisons
of the relative intensities of the 1D NMR signals between disease and healthy samples.
While the use of relaxation edited techniques such as the Carr-Purcell-Meiboom-Gill
(CPMG) experiment, serum/ plasma deproteinization, and line fitting approaches
24

significantly improves the analysis of metabolites,

such methods are not ideal.

Diffusion-sensitized 1D NMR spectroscopy, which uses data from two separate 1D
experiments, one obtained using low diffusion gradients and the other using high
gradients to suppress macromolecular background signals effectively, was shown to be
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useful for the quantitative analysis of blood plasma metabolites.

However, spectral

overlap still significantly limits the number of metabolites that can be analyzed. 2D NMR
promises quantitative analysis of a large number of metabolites on a routine basis. An
important requirement is that the cross-peaks in 2D spectra should be devoid of overlaps
for reliable quantitative results; however, this criterion is not often met for a large number
of metabolites by a single 2D experiment due to the extremely high complexity of
plasma. The advantage of the new 2D NMR approaches used here is that the use
chemoselective isotope tags greatly reduces the complexity of the spectra, since only a
single peak is observed for the metabolites with a single functional group (see Figures 2.3
and 2.7). The reduced complexity of the spectra due to the absence of less interesting
chemical signals is particularly important for the analysis of low- concentration
metabolites (Figures 2.4 and 2.8). This method, however, does not work for the analysis
of lipoproteins, which represents a major class of metabolites in blood plasma and which
have been effectively analyzed using a multivariate deconvolution approach.26,27
An important criterion for the quantitative analysis method to be robust is that it
does not require the use of spiking standards for each sample. To test this, we also
determined the concentration of

15

N and

13

C isotope tagged metabolites in plasma by

comparing the 2D peak integrals with those from the synthetic analogues. It may be
interesting to note that, as shown in Figure 2.9, the values determined using both 15N and
13

C isotope tagging agree well with those determined on the basis of spiking with

synthetic analogues. Therefore, it is sufficient to obtain the integral for each synthetic
analogue only once, which can be used for the analysis of any number of samples.
Utilization of 2D HSQC experiments involving the isotopes has the additional advantage
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since both the magnitude of the coupling and the relaxation properties of the nuclear pairs
(15N/

13

C and 1H) do not appreciably vary across the metabolites of interest and, hence,

provide the relative cross peak intensities that are less sensitive to instrumental settings.
In this study, we quantified 27 metabolites with an average CV of 2.4% for 17
metabolites and 5.6% when all the metabolites were considered. When the results from
all the four NMR methods were combined for the same metabolites, the average CV’s
were 4.8% and 8.7%, respectively. We note that, as the metabolite library expands, we
can quantify additional metabolites from the same and already acquired 2D data by
comparison of the peak integrals with those from the standards. Mass spectrometry (MS),
another very useful method for quantitative analysis, is highly sensitive and provides
quantitative information on a larger number of metabolites. However, MS invariably
involves the combination of a separation method such as gas chromatography or liquid
chromatography for accurate analysis and often renders the obtained results to be
sensitive to the specific column and separation parameters and especially the ionization
conditions. In addition, a standard compound is needed for each quantified metabolite.
In conclusion, this investigation presents quantitative analysis of over 25 plasma
metabolites using

15

N and

13

C isotope tagging methods. Carboxylic acids and amines

represent a majority of the metabolites in body fluids, and their analysis by isotope
tagging significantly enhances the detectable metabolic pool for biomarker discovery
applications. The combination of improved sensitivity and resolution and the reduced
time required when compared to natural abundance heteronuclear NMR methods are
attractive for the routine and accurate analysis of metabolites in complex biological
samples. Although, the isotope tagging methods use 2D NMR experiments, each 2D
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experiment requires only 30 min or less (~10 min with a cryoprobe), and hence, the
approach can be useful for high throughput analysis of human plasma as well as other
biological fluids. Further, combination of the isotope tagging approach with the latest
advancements in NMR technology, such as detection using microcoil probes, for
example, can significantly minimize the volume of biofluid samples required for routine
analysis.
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Table. 2.1 Synthetic analogues of metabolites used for the quantitative analyses of human
plasma metabolites
Serial
Standard
Estimated approximate blood
Actual NMR calibrated concentrations
number
compound
plasma concentrationsa (μM)
in the mixture (μM) used for spikingb
1
3-hydroxybutyrate
60
59.2 ± 0.9
2
acetate
80
73.7 ± 1.1
3
l-alanine
300
287.1 ± 4.5
4
l-arginine
80
90.1 ± 1.4
5
citrate
30
28.1 ± 0.4
6
creatinine
40
31.6 ± 0.6
7
formate
40
32.5 ± 0.5
8
l-glutamic acid
50
53.8 ± 0.3
9
l-glutamine
300
292.1 ± 2.8
10
l-glycine
200
172.6 ± 2.7
11
l-histidine
80
83.7 ± 0.6
12
l-isoleucine
50
50.7 ± 0.2
13
lactate
1000
959.5 ± 15.1
14
l-leucine
80
80.7 ± 1.2
15
l-lysine
100
75.3 ± 2.3
16
l-methionine
20
19.2 ± 0.03
17
l-phenylalanine
70
71.1 ± 1.1
18
l-proline
100
93.3 ± 1.5
19
l-threonine
100
90.0 ± 1.9
20
L-tryptophan
30
29.1 ± 0.4
21
l-tyrosine
80
80.9 ± 0.3
22
l-valine
200
183.2 ± 1.5
23
succinate
10
9.9 ± 0.1
24
betaine
50
44.6 ± 0.7
25
4-hydroxy proline
50
53.4 ± 0.8
26
l-serine
100
93.3 ± 0.7
27
l-asparagine
40
43.9 ± 0.7
28
taurine
30
27.7 ± 0.1
a Obtained from the combination of database search and comparison of the relative peak integrals in the NMR spectra.
b The errors are standard deviations from two measurements.
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Table. 2.2 Concentration of synthetic analogues of human plasma metabolites before and
after calibration using 1H NMR
Serial Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
30
31
32

Metabolites
3-Hydroxybutyrate
Acetate
L-Alanine
L-Arginine
Citrate
Creatinine
Formate
L-Glutamic acid
L-Glutamine
L-Glycine
L-Histidine
L-Isoleucine
Lactate
L-Leucine
L-Lysine
L-Methionine
L-Phenylalanine
L-Proline
L-Threonine
L-Tryptophan
L-Tyrosine
L-Valine
Succinate
Betaine
4-hydroxy-proline
L-Serine
L-Asparagine
Taurine
Ethanolamine
Maleic acid
DSS

Concentration from
the weight (mM)*
20.02
19.62
19.67
20
20.09
20.15
20.38
20.18
20.15
20.58
20.1
20.24
20.21
20.37
20.11
19.95
20
20.16
19.98
20
19.87
20.07
20.03
20.15
20
19.98
20.01
19.94
20
20.07
5

Concentration after calibration
by 1H NMR (mM)*
20.69 ± 0.32
19.33 ± 0.30
20.07 ± 0.31
23.62 ± 0.37
19.67 ± 0.31
16.18 ± 0.30
17.02 ± 0.26
22.39 ± 0.12
20.33 ± 0.19
18.09 ± 0.28
21.83 ± 0.17
21.07 ± 0.09
20.12 ± 0.31
21.16 ± 0.33
15.98 ± 0.49
19.96 ± 0.03
21.29 ± 0.33
19.57 ± 0.31
18.95 ± 0.41
20.36 ± 0.32
21.04 ± 0.08
19.10 ± 0.15
20.77 ± 0.33
18.69 ± 0.30
22.39 ± 0.35
19.45 ± 0.14
23.01 ± 0.36
19.17 ± 0.07
20.34 ± 0.95
20.85 ± 0.31
4.70 ± 0.02
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Table. 2.3 Synthetic analogues of human plasma metabolites grouped for concentration
calibration using 1H NMR
Group 1

Group 2

Group 3

Group 4

Group 5

3-Hydroxybutyrate

L-Arginine

L-Glutamine

Creatinine

Succinate

Acetate

L-Histidine

L-Isoleucine

L-Glutamic acid

L-Serine

L-Alanine

Lactate

L-Threonine

L-Lysine

Taurine

Citrate

L-Phenylalanine

L-Tryptophan

L-Methionine

Formate

L-Tyrosine

Ethanolamine

L-Proline

L-Glycine

L-Valine

L-Leucine

4-Hydroxy-proline

Betaine

Maleic acid

L-Asparagine
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Table. 2.4 1H, 13C, and 15N chemical shifts of the peaks used in the analysis of NIST
plasma metabolites
1

H−15N HSQC

label

metabolite

1

H−13C HSQC

1

H (ppm)

15

N (ppm)

label

1

metabolite

13

H (ppm)

C (ppm)

2

acetate

8.01

120.93

3

l-alanine

7.96

163.4

3

l-alanine

8.23

113.7

10

l-glycine

8.03

164.15

5

citrate

8.04

122.62

11

l-histidine

7.97

163.56

8

l-glutamic acid

8.21

115.58

12

l-isoleucine

8.03

163.81

10

l-glycine

8.12

114.78

18

l-proline

8.1

163.1

11

l-histidine

8.25

116.42

19

l-threonine

8.12

164.12

17

l-phenylalanine

8.13

117.19

20

l-tryptophan

7.88

163.51

19

l-threonine

8.28

117.52

22

8.05

163.88

20

l-tryptophan

8.03

116.9

25

l-valine
4-hydroxy
proline

8.04

165.21

21

l-tyrosine

8.18

117.25

26

l-serine

8.07

163.92

22

l-valine

8.3

118.43

27

l-asparagine

8.01

163.57

24

betaine

8.57

124.28

28

taurine

7.99

164.23

1

H 1D NMR

1

1

H− H TOCSY
1

H (ppm)

label

1

1

H (ppm)

1

metabolite
3hydroxybutyrate

H (ppm)

label

metabolite

F2 dimension

F1 dimension

1.19

4

l-arginine

1.68

3.23

2

acetate

1.91

5

citrate

2.65

2.51

3

l-alanine

1.47

11

l-histidine

7.07

7.06

7

formate

8.45

12

l-isoleucine

3.66

0.98

9

l-glutamine

2.13

13

lactate

1.32

1.32

11

l-histidine

7.06

14

l-leucine

0.95

1.7

12

l-isoleucine

1.01

15

l-lysine

3.02

1.48

16

l-methionine

2.13

19

l-threonine

3.57

1.33

17

l-phenylalanine

7.42

20

l-tryptophan

7.53

7.72

20

l-tryptophan

7.74

21

l-tyrosine

6.9

7.18

21

l-tyrosine

6.89

22

l-valine

3.6

2.27

22

l-valine

1.03
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Table. 2.5 NIST plasma metabolite concentrations obtained using a combination of NMR
experiments with or without isotope tagging
label
1
2
3

metabolite

NIST plasma
concentration (μM)a

3-hydroxybutyratee

99.3 ± 13.1

acetate

be

l-alanine

142.0 ± 3.0
bce

4

l-arginine

5

citratebd

7
8

formate

279.4 ± 18.9

d

e

l-glutamic acid
e

16
17
18

NIST plasma
concentration (μM)a

metabolite
l-methioninee
l-phenylalanine
l-proline

19

l-threonine

20

l-tryptophanbcde

69.3 ± 5.3

l-tyrosine

bde

l-valine

b

107.3 ± 16.7
45.9 ± 8.1
58.9 ± 7.2

bcde

22

50.6 ± 3.8
127.6 ± 13.1

bcd

155.9 ± 16.0

21

16.6 ± 2.8
be

c

40.1 ± 2.3
51.2 ± 2.1
b

label

159.7 ± 11.6

9

l-glutamine

368.5 ± 2.3

24

betaine

10

l-glycinebc

204.5 ± 31.2

25

4-hydroxy prolinebc

11.5 ± 1.3

11

l-histidinebcde

63.1 ± 5.7

26

l-serinec

95.8 ± 15.0

12

l-isoleucine
d

13

lactate

14

l-leucined
d

cde

48.2 ± 2.4

27

l-asparagine
c

2403.6 ± 127.6

28

taurine

100.1 ± 0.1

29

glucosee

27.3 ± 2.8

c

33.4 ± 2.8
32.4 ± 0.8
8778.5 ± 62.8

190.8 ± 21.9
15
l-lysine
a The errors are standard deviations.
b Obtained from 1H−15N HSQC.
c Obtained from 1H−13C HSQC.
d Obtained from 1H−1H TOCSY.
e Obtained from 1H 1D NMR.
Two samples were used for each type of experiment resulting in two, four, six, or eight independent measurements for
each metabolite.
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Figure 2.1 Flow chart depicting the steps followed in the analysis of the standard
metabolite mixture using isotope enhanced NMR methods.
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Figure 2.2 Flow chart depicting the steps followed in the analysis of metabolites in the
NIST plasma sample using isotope enhanced NMR methods.
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Figure 2.3 2D spectra of mixtures of 28 synthetic compounds obtained with or without
isotope tagging: (a) 1H−15N HSQC spectrum with15N tagging of carboxylic acids,
(b)1H−13C HSQC spectrum with 13C tagging of amines and amino acids, and (c) 1H−1H
TOCSY spectrum of the neat mixture. All the spectra were obtained on an 800 MHz
spectrometer. The labeled peaks correspond to the numbered metabolites in Table 2.1.
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Figure 2.4 Concentration of 28 standard metabolites obtained by combining 2D NMR
experiments with and without 15N or 13C tagging: (a) obtained from 1H−15N HSQC NMR
after 15N tagging; (b) obtained from 1H−13C HSQC NMR after 13C tagging, and (c)
obtained from 1H−1H TOCSY NMR of the neat mixture. The shaded bar on the right in
each pair represents the actual concentration of the metabolite.

Expected Concentration (µM)
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Concentration from 2D NMR Methods (µM)

Figure 2.5 Correlation of the concentration of the metabolites determined by a
combination of 2D experiments with or without 15N or 13C tagging with the expected
values.
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Figure 2.6 1D 1H NMR spectrum of aqueous metabolites of NIST plasma obtained on a
Bruker 500 MHz NMR spectrometer.
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Figure 2.7 2D spectra of NIST plasma obtained with and without isotope tagging: (a)
H−15N HSQC spectrum obtained after 15N tagging of carboxylic acids, (b)1H−13C HSQC
spectrum obtained after 13C tagging of amines and amino acids, and (c) 1H−1H TOCSY
spectrum of the neat mixture. All the spectra were obtained on an 800 MHz spectrometer.
The labeled peaks correspond to the numbered metabolites in Table 2.1.
1
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Figure 2.8 Concentrations of metabolites in the NIST plasma obtained using 1D/2D
NMR experiments with and without isotope tagging: (a) obtained from 1H−15N HSQC
NMR after 15N tagging, (b) obtained from 1H−13C HSQC NMR after 13C tagging, (c)
obtained from 1H−1H TOCSY NMR of neat plasma, and (d) obtained from 1D NMR of
the neat plasma sample.
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Figure 2.9 Comparison of the concentrations of (a) carboxylic acid and (b) amino group
containing metabolites in the NIST plasma obtained with spiking (left bars) and without
spiking (right bars) with the standard compounds.
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CHAPTER 3: METABOLITE PROFILING OF THE CARBOXYL-CONTAINING
METABOLITES WITH SMART ISOTOPE TAGGING

3.1 Introduction
The metabolomics field has witnessed an exponential growth since the last decade
due to its potential applications in numerous disciplines including biomedicine,
toxicology, food and nutrition, drug development and environmental science.1-5
Commonly

used analytical techniques such as nuclear magnetic resonance (NMR)

spectroscopy and/or mass spectrometry (MS) have evolved in response to the high
demand for resolving the complexity of biological mixtures and identifying the large pool
of quantifiable metabolites. However, despite numerous advances, the biological
complexity still often outweighs the capabilities of these advanced analytical methods; no
single technique currently is capable of detecting all metabolites in a single experiment.
Each analytical method is sensitive to certain classes of metabolites, and depending on
the nature of the metabolites of interest, generally one or sometimes a combination of
NMR or MS techniques are used to profile as many metabolites as possible and thereby
derive the biological meaning. A major hurdle of such an approach is that the metabolite
data obtained from NMR and LC-MS or GC-MS methods for the same or similar samples
are often not directly comparable. The inability to compare and correlate data from
different analytical techniques for the same or similar samples is a significant challenge
that prevents drawing meaningful conclusions from the vast amount of metabolite data
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existing in the literature and exploiting the combined strength of NMR and MS for
unknown metabolite identification. The main contributing factors for this bottleneck are
the limited NMR sensitivity, complex spectral signatures and variable MS ionization
efficiency or suppression.
The use of chemo-selective tags provides an avenue to improve the sensitivity of
metabolite detection by both NMR and MS methods. For example, the sensitivity of MS
detection is shown to be enhanced by three orders of magnitude or more by tagging
metabolites with a chemo-selective tags containing a permanent charge.6-10 Because of
the permanent charge, the tagged metabolites are effectively detected with high
sensitivity and better quantitative accuracy, irrespective of the pH or nature of the
solvents used to separate metabolites before detection by MS. Separately, based on
differential dansylation using 12C/13C-dansyl chloride, absolute or relative quantitation of
amine and phenol containing metabolites has been achieved with a sensitivity
enhancement of three orders of magnitude.11,12 Similarly, NMR-sensitive isotope based
chemo-selective tags have been shown to detect many quantifiable metabolites with high
sensitivity and resolution by NMR.13-17 Using 15N-ethanolamine as the tag, for example,
over a hundred carboxyl-containing metabolites have been detected by 1H-15N twodimensional NMR with high resolution and sensitivity.13 However, while metabolites can
be detected with high sensitivity by both MS and NMR separately using chemoselective
tags, the inability to compare and correlate the data from the two methods is a major
bottleneck in the metabolomics field.
The ability to more easily detect the same metabolites by both NMR and MS
methods would offer new avenues to compare data between MS and NMR platforms and
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to exploit the combined strength of the complimentary methods. Towards this goal, we
introduce a new “smart isotope tag” approach, using

15

N-cholamine in this case, which

possesses the characteristics of high NMR sensitivity and resolution through its isotope
enrichment and high MS sensitivity through its permanent positive charge (see schematic
Figure 3.1). The tag combines the strengths of individual chemo-selective tags,
demonstrated previously and separately for NMR and MS detection,6, 13 and offers news
avenues to exploit the combined strength of these powerful and complementary
techniques for areas such as metabolite profiling and unknown metabolite identification.

3.2 Materials and Methods

3.2.1 Chemicals and Biofluids
A total of 48 carboxyl-containing metabolite standards (Table 1), (2bromoethyl)trimethylammonium

bromide,

dimethylformamide

(DMF),

methanol,

acetonitrile, isopropanol, acetone, hydrochloric acid (HCl), sodium hydroxide (NaOH)
(all from Sigma-Aldrich, St. Louis, MO), 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4methylmorpholinium chloride (DMTMM) (Acros Organic, Pittsburgh, PA),

15

N-

phthalimide potassium and deuterium oxide (Cambridge Isotope Laboratories, Andover,
MA) were used without further purification. Human serum samples were obtained from
Innovative Research, Inc. (Novi, MI) and urine from healthy volunteers, in accordance
with the Internal Review Board at Purdue University. Deionized (DI) water was from inhouse Synergy Ultrapure Water System from Millipore (Billerica, MA).
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3.2.2 Design and Synthesis of the Smart Isotope Tag 15N-cholamine
Synthesis of 15N-cholamine involved a two-step reaction and followed the Gabriel
synthesis procedure with modifications as described below to yield the pure product.18,19
The

first

step

involved

reacting

potassium

15

N-phthalimide

(2-bromoethyl)trimethylammonium bromide in DMF to obtain the

15

with

N substituted

phthalimide intermediate (Scheme 1). The second step involved alkaline and acid
hydrolyses of the
15

15

N substituted phthalimide to yield the smart isotope tag,

N-cholaimne (Scheme 2).

Scheme 3.1 Synthesis of 15N substituted phthalimide

Scheme 3.2 Alkaline and acid hydrolyses of the 15N substituted phthalimide to yield
15
N-cholamine

Briefly, for the synthesis of

15

N substituted phthalimide (Scheme 1), (2-

bromoethyl)trimethylammonium bromide (9.5 mmol, 2.35 g) was mixed with
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15

N-phthalimide potassium (10 mmol, 1.86 g) in a 250 mL round bottom flask and dry

DMF (100 mL) was added under nitrogen gas. The mixture was then refluxed at 100 °C
with stirring for 12 h. The supernatant from the reaction mixture was separated and the
solvent was removed using a rotary evaporator.18 The resulting crude residue was washed
thrice using acetonitrile (5 mL each time), twice with acetone (2 mL each time) followed
by washing again once with acetonitrile (3 mL) to obtain the pure

15

N-substituted

phthalimide. 1H NMR spectra in D2O at each step were monitored to assess the purity of
the intermediate product. For the synthesis of
15

15

N-cholamine, in the second step, the

N-substituted phthalimide (538 mg) (Scheme 1) was dissolved in DI water (24 mL);

1 N NaOH (2.69 mL) was added to the solution and the mixture was left at room
temperature with stirring for 30 min to complete the alkaline hydrolysis (Scheme 2).19
Subsequently, 12 N HCl (1.8 mL) was added to the solution, the temperature was raised
to 70C and left for 12 h with stirring to complete the acid hydrolysis (Scheme 2).19 The
solvent was then removed using a rotary evaporator. The resulting crude residue was
washed thrice with acetonitrile (4 mL each time) followed by washing thrice with 25:75
water/acetone mixture (2 mL each time) to yield the pure product,

15

N-cholamine. 1H

NMR spectra in D2O at each step were monitored to assess the purity of the final product.

3.2.3 Tagging Metabolites Using the Smart Isotope Tag 15N-cholamine
15

N-cholamine (5mg, 50 μmol) was added to 500 μL sample in an eppendorf tube,

the pH of the mixture was adjusted to 7.0 with 1 M HCl or NaOH. 21 mg DMTMM was
added to initiate the reaction.13,20,21 The mixture was stirred at room temperature for 4 h
to complete the reaction. The general reaction for tagging metabolites with the smart
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isotope tag is shown in Scheme 3. To maintain 15N amide protonation, the pH was
adjusted to 5.0 by adding 1 M HCl or 1 M NaOH, and the solution volume was adjusted
to 580 μL by adding DI water and 30 μL of D2O prior to NMR detection. Serum was
deproteinized using methanol prior to metabolite tagging and urine was used with no
pretreatment.13

Scheme 3.3 General reaction for tagging carboxyl-containing metabolites with the smart
isotope tag- 15N-cholamine

3.2.4 NMR Spectroscopy
For each sample, 550 μl was mixed with 30 μl D2O and placed in a 5 mm NMR
tube. NMR experiments were performed on a Bruker DRX 500 MHz or Avance III 800
spectrometer equipped with a room temperature or cryoprobe probe, respectively,
suitable for 1H inverse detection with Z-gradients at 298 K. A one pulse sequence with or
without solvent signal suppression using presaturation was used for 1H 1D NMR
experiments. The sensitivity-enhanced 1H-15N 2D HSQC experiments employed an
INEPT transfer delay of 6 ms corresponding to the JNH of 90 Hz. Spectral widths for the
1

H and

15

N dimensions were approximately 8 kHz and 3 kHz, respectively. 128 free

induction decays of 1,024 data points each were collected in the indirect (t1) dimension
with 1 or 4 transients per increment. Nitrogen decoupling during the direct acquisition (t2
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dimension) was achieved with the GARP (Globally Optimized Alternating-Phase
Rectangular Pulses) sequence. The resulting 2D data were zero-filled to 1,024 points in
the t1 dimension after forward linear prediction to 256 or 512 points. A 45° shifted sinebell window function was applied to both dimensions before Fourier transformation.
Chemical shifts were referenced to the 1H signal of TSP for the 1D spectra or the
derivatized formic acid signal (1H: 8.05 ppm;

15

N: 123.93 ppm) in the HSQC spectra.

Bruker Topspin versions 3.0 or 3.1 software packages were used for NMR data
acquisition or processing.

3.2.5 Mass spectrometry
LC-MS and LC-MS/MS experiments were performed using an Agilent 1200 SLLC system coupled online with an Agilent 6520 Q-TOF mass spectrometer (Agilent
Technologies, Santa Clara, CA). The sample (8 µL) was injected onto an Agilent
Poroshell 120 EC-C18 column (30x50 mm, 2.7-micron), which was heated to 50 °C. The
flow rate was 0.5 mL/min. Mobile phase A was 5 mM ammonium acetate in water, and
mobile phase B was 0.1% water in ACN. The mobile phase composition was initially
kept isocratic at 3% B for 1 min, then increased to 90% B over 4 min; after another 4 min
at 90% B, the mobile phase composition returned to 3% B. Electrospray ionization (ESI)
was used in positive mode, and the voltage was 3.5 kV. The mass analyzer was scanned
over a range of 50–1000 m/z. The collision energy for auto LC-MS/MS experiments was
fixed at 10 V, targeting pre-selected compounds.
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3.3 Results and Discussion
The smart isotope tag, 15N-cholamine, designed, developed and used in this study
retains all the characteristics of the

15

N-ethanolamine tag including the solubility of the

tagged metabolites in aqueous media, large one-bond J-coupling between 1H and

15

N of

~90 Hz for efficient polarization transfer between 1H and 15N nuclei, and wide chemical
shift dispersion for different metabolites in the resulting 2D NMR spectra.13 In addition,
and importantly,

15

N-cholamine possesses a permanent positive charge, which enables

efficient positive mode detection of the same carboxyl-containing metabolites by MS,
irrespective of the pH or solvent conditions of the eluting media, commonly used for
chromatographic separation before detection by MS.6
Synthesis of 15N-cholamine involved a two-step reaction and followed the Gabriel
synthesis procedure with suitable modifications to yield the pure product.18, 19 As seen in
the 1H NMR spectrum (Figure 3.2), the pure intermediate compound,

15

N substituted

phthalimide, was obtained after the first step of the synthesis. Hydrolysis of this
compound yielded the

15

N-cholamine in pure form as can be ascertained from its 1H

NMR spectrum (Figure 3.3; peaks at 3.16; 3.48; 3.64 ppm). The accurate MS and
MS/MS spectra for

15

N-cholamine, shown in Supplementary Figure 3.4, help further

verify the identity and purity of the synthesized smart isotope tag (m/z= 104.120).
The compound was then used to tag 48 metabolites that were selected for their
prominence as carboxyl-containing metabolites in biofluids that represent a variety of
metabolic pathways. The general reaction for tagging metabolites with the smart isotope
tag is shown in Scheme 3. To maintain 15N amide protonation, the pH was adjusted to 5.0
by adding 1 M HCl or 1 M NaOH, and the solution volume was adjusted to 580 μL by
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adding DI water and 30 μL of D2O prior to NMR detection. Serum was deproteinized
using methanol prior to metabolite tagging and urine was used with no pretreatment.13
The 1H and 15N chemical shift data derived from the 2D NMR experiments, after
tagging with 15N cholamine, are shown in Table 3.1. Because the 15N-cholamine and the
previously used

15

N-ethanolamine differ only in their terminal group, the tagging

efficiency, reproducibility and chemical shift values for metabolites with 15N-cholamine
tag were similar to those obtained using the 15N-ethanolamine tag.13
Importantly, as anticipated based on the
shown earlier in our laboratory,13 the

15

15

N-ethanolimane tagging approach

N-cholamine tagging of metabolites in human

serum provided a rich NMR spectrum due to the large number of carboxyl-containing
metabolites normally present in blood (Figure 3.5). The low natural abundance of

15

N

(0.37%) ensures that none of the nitrogen containing metabolites interferes with the
detection of carboxyl-metabolites through 15N-cholamine tag. Each peak in the spectrum
corresponds to different metabolite from the carboxylic acid class. However, metabolites,
which contain more than one carboxyl group, provide additional peaks depending on the
number of carboxyl groups and molecular symmetry. In addition, metabolites such as
lactate, which possess -hydroxyl groups, show more than one peak for the same
metabolite as we described earlier using the

15

N-ethanolmaine tag.13 Some of the peaks

assigned based on the chemical shift values for the standard compounds are marked with
the corresponding number shown in Table 3.1 and Figure 3.6. Similarly, tagging of
metabolites in human urine with

15

N-cholamine also enabled the detection of peaks

corresponding to well over a hundred carboxylic acid group containing metabolites
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(Figure 3.7). Peaks tentatively assigned based on the values for the standard compounds
are marked by their numbers shown in Table 3.1 and Figure 3.6.
The 15N-cholamine tagging of metabolites in aqueous media enabled a sensitivity
enhancement of up to three orders of magnitude or more in the MS detection of carboxyl
metabolites. The derivatized metabolites could be detected easily in positive ion mode as
compared to the same metabolites detected in negative ion mode without the tag. For
example, the sensitivity for pyruvic acid detected in positive ion mode after

15

N-

cholamine tagging was enhanced by a factor of about 1500 when compared to that
detected for the same metabolite without the

15

N-cholamine tag, in negative ion mode.

Figure 3.8 shows typical mass spectra for formic acid and pyruvic acid after tagging with
15

N-cholamine. The enhancement in sensitivity is primarily due to the high ionization

efficiency imparted by the permanent positive charge of the

15

N-cholamine and is in

agreement with results by Smith and co-workers for fatty acid analysis using the heavy
and light forms of cholamine.6 In that study, reactions of metabolites with cholamine
were made in organic solution in contrast to the aqueous media used here. The

15

N-

cholamine derivatized serum samples were then analyzed by LC-MS. As anticipated, due
to the presence of the permanent positive charge, tagged metabolites could be readily
detected in positive ion mode with high sensitivity. Sensitivity enhancement by a factor
of up to nearly 3000 could be achieved for tagged acids. The extracted ion
chromatograms for a few typical carboxylic acids detected in serum with 15N-cholamine
tag are shown in the Supplementary Figure 3.9.
One potential issue is the effect on chromatographic retention time caused by the
addition of the cholamine tag. However, separation of the tagged metabolites using

72
HILIC columns offers opportunity to effectively separate before detection using MS. For
example, the results of separation of a mixture of standard carboxylic and amino acids
performed using a HILIC column, without attempting to optimize chromatography
conditions, indicate that

15

N-cholamine tagged metabolites can be separated effectively

(Figure 3.10). More broadly, we can contemplate the use of dual purpose smart tags for
other NMR-MS combinations. For GC-MS, the addition of a charged species will likely
cause problems related to reduced volatility; however, a different tag, such as 13C or even
29

Si labeled silyl-type tags can be contemplated.23 Another alternative is the use of smart

tags for capillary electrophoresis (CE) coupled to MS, which is increasingly of interest in
metabolomics.24 In fact, positively charged derivatization agents (based on pyridinum
containing compounds) have been demonstrated for the use of metabolite profiling of
carboxylic acids by CE-MS.25 Thus, the potential for the use of smart tags such as
cholamine for CE-MS and NMR is quite promising.
In conclusion, we have developed a smart isotope tag,

15

N-cholamine, which

possesses dual characteristics for metabolite profiling in complex biological mixtures
using the powerful analytical techniques of NMR and MS. By combining the individual
strengths of the 15N label and permanent charge, the smart isotope tag facilitates detection
of carboxyl-containing metabolome by both NMR and LC-MS techniques with high
sensitivity. Detection of the same metabolites by both NMR and MS (Figure 3.11),
effectively opens unique opportunities for identification of unknown metabolites and
direct comparison of metabolite data from the two powerful analytical platforms.
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Table. 3.1 1H and 15N NMR chemical shifts for 15N-cholamine tagged carboxyl-containing
metabolites measured with reference to the formic acid peak
Label

1

Name

Cis-Aconitic acid

1

H
(ppm)

15

N
(ppm)

Label

Name

15

H
(ppm)

N
(ppm)
117.51

1

8.5

118.24

23

2-hydroxyisobutyric acid

7.95

8.14

121.47

24

DL-Isocitric acid

8.40

117.15

8.06

119.49

8.11

120.77

8.07

120.21

8.28

122.78

8.23

116.00

8.04

117.88

8.14

120.81

25

Isoleucine

8.37

118.19

2

Adipic acid

8.05

120.57

26

Isovaleric acid

8.07

121.92

3

DL-Alanine

8.30

114.39

27

α-Ketoglutaric acid

8.69

116.34

4

4-Aminobenzoic acid

8.25

111.35

8.63

111.84

5

Arginine

8.34

115.96

28

Lactic acid

6

Asparagine

8.31

116.03

7

Aspartic acid

8.23

114.18

8.49

114.45

8.15

120.01

29

Leucine

8.34

115.24

8.38

115.27

30

Lysine

8.33

115.88

8.31

115.6

31

Maleic acid

8.39

120.39

8.16

121.35

32

Malic acid

8.28

122.83

8.29

115.14

8

Betaine

8.55

122.69

9

Citric acid

8.20

121.46

33

Malonic acid

8.19

121.44

8.07

123.95

34

Methionine

8.36

116.08
117.13

7.87

121.88

35

Oxalic acid

8.47

10

Cysteine

8.35

115.93

36

Oxaloacetic acid

8.35

112.67

11

Cystine

8.5

115.22

8.63

111.40

12

Formic acid

8.05

123.93

37

L-phenylalanine

8.21

118.85

13

Fumaric acid

8.42

122.68

38

L-proline

8.35

115.58

8.56

124.24

39

Propionic acid

7.95

118.85

14

Glucuronic acid

8.38

119.54

40

Pyroglutamic acid

8.29

115.88

15

Glutamic acid

8.28

115.99

41

Pyruvic acid

8.63

111.39

8.05

120.42

8.35

112.72

16

Glutamine

8.35

115.90

42

Serine

8.17

117.63

17

Glycine

8.2

115.45

43

Succinic acid

7.97

119.56

18

Glycolic acid

8.22

114.97

44

Succinyl-COA

7.78

123.45

8.37

115.19

45

L-threonine

8.34

117.79

19

Hippuric acid

8.2

115.62

46

L-tryptophan

7.98

119.37

20

Histidine

8.36

116.60

47

Tyrosine

8.27

118.05

21

3-Hydroxybutyric acid

8.07

122.20

48

Valine

8.38

118.20

22

4-Hydroxy-L-proline

8.5

115.89

8.36

117.62
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Figure 3.1 Schematic figure illustrating the “smart isotope tag” approach used to detect
the same metabolites using NMR and MS with high sensitivity. Tagging carboxylcontaining metabolites with 15N-cholamine enables their detection by both NMR and MS
with high sensitivity.
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Figure 3.2 1H NMR spectrum of 15N-substituted phthalimide intermediate compound,
obtained for the synthesis of 15N-cholamine, recorded on a Bruker DRX 499 MHz NMR
spectrometer.
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Figure 3.3 1H NMR spectrum of the synthesized 15N-cholamine obtained on a Bruker
Avance III 800 MHz NMR spectrometer.
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Figure 3.4 MS and MS/MS spectra of the synthesized 15N-cholamine.
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Figure 3.5 A portion of the 1H-15N HSQC spectrum of human serum tagged with 15Ncholamine. 1: aconitic acid; 2: adipic acid; 3: alanine; 7: aspartic acid; 8: betaine; 9: citric
acid; 11: cystine; 12: formic acid; 15: glutamic acid; 17: glycine; 20; histidine; 21: 3hydroxybutyric acid; 24: isocitric acid; 28: lactic acid; 29: leucine; 32: malic acid; 37:
phenylalanine; 40: pyroglutamic acid; 45: threonine; 46: tryptophan; 47: tyrosine; 48:
valine.
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Figure 3.6 A portion of the 1H-15N HSQC spectrum of a mixture of standard compounds
at various concentrations obtained after tagging with 15N-cholamine. The peak numbers
correspond to the compounds shown in Table 3.1.
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Figure 3.7 A portion of the 1H-15N HSQC spectrum of human urine tagged with 15Ncholamine. 1: aconitic acid; 2: adipic acid; 3: alanine; 5: arginine; 6: asparagine; 7:
aspartic acid; 9: citric acid; 12: formic acid; 15: glutamic acid; 18: glycolic acid; 19:
hippuric acid; 24: isocitric acid; 28: lactic acid; 33: malonic acid; 39: propionic acid; 40:
pyroglutamic acid; 43: succinic acid; 45: threonine; 46: tryptophan.
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Expected mass (M+) = 132.115473
Observed mass (M+) = 132.114786
Formic acid

Expected mass (M+) = 174.126038
Observed mass (M+) = 174.125457
Pyruvic acid

Figure 3.8 Typical LC-QTOF-MS spectra for formic acid and pyruvic acid obtained after
tagging with the smart isotope tag, 15N-cholamine. The permanent charge on the tagged
metabolites enables their sensitive detection; the observed peak is from the intact tagged
metabolite.
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Figure 3.9 Accurate mass extracted ion chromatograms for a few carboxylic acids
detected in serum in positive ion mode after tagging with 15N-cholamine. The sensitivity
enhancement factor indicates the ratio of peak area obtained with 15N-cholamine tag to
the peak area for the same acid detected without tagging (in negative ion mode), in the
same serum sample.
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Formic acid

Acetic acid
Glycine
Pyruvic acid
Lactic acid

Threonine

Lysine
Phenylalanine
Tyrosine

Figure 3.10 MRM chromatograms for a mixture of cholamine tagged carboxylic and
amino acids detected after separation using an HILIC column, without attempting to
optimize chromatography conditions. Considering that all metabolites have the same
permanently charged cholamine tag, the separation achieved in a quick experiment which
is still not well optimized may be remarkable.
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Figure 3.11 Two examples comparing the MS and NMR peak integral intensities for
formic and pyruvic acids at different concentrations. Eight mixtures with random
concentrations of various synthetic compounds were tagged with 15N-cholamine and
analyzed using NMR and MS methods. Good correlation between the NMR and MS
measurements, as seen in the two figures, suggest the potential of using the new tagging
approach for direct comparisons of the data from the two analytical platforms.
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CHAPTER 4. APPLICATION OF HIGH-RESOLUTION MAGIC ANGLE
SPINNING NUCLEAR MAGNETIC RESONANCE (HR-MAS NMR)
SPECTROSCOPY FOR BREAST CANCER METABOLITE PROFILING OF
AFRICAN AMERICAN COMPARE TO CAUCASIAN WOMEN

4.1 Introduction
Breast

cancer

is

a

heterogeneous

group

of

diseases

that

are

immunohistochemically subtyped by cancer cell expression of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2).
These subtypes are recognized as: ER or PR positive and HER-2 negative subtype (ER+,
PR+, HER-2-); ER or PR positive and HER-2 positive subtype (ER+, PR+, HER-2+);
and ER, PR, and HER-2 negative (triple-negative breast cancer).1,2 These subtypes not
only differ in hormonal status and HER-2 expression but also clinically in their prognosis
and response to therapy3 as well as incidence rates. The incidence rates of triple negative
cancer are higher in African American compared to Caucasian women, while Caucasian
women have higher rates of ER-positive subtypes.4
Triple negative breast cancer (TNBC) constitutes about 10-20% of diagnosed
breast cancer and is also more prevalent in younger women. Despite the small percentage
of TNBC, it causes a disproportionate number of breast cancer deaths.

This high

mortality is due to the aggressive nature of the subtype that includes earlier relapses and a
distinct pattern of metastasis.5
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Because of the lack of hormonal receptors (ER and PR) and HER-2 receptor,
TNBC is not responsive to treatment with hormone or anti-HER-2 monoclonal antibody
therapy. Currently, TNBC treatment is limited to systemic cytotoxic chemotherapy.
Interestingly, patients with TNBC treated with neoadjuvant chemotherapy and who show
a pathologic complete response (pCR) show significant improvements in both diseasefree survival and overall survival compared with patients with residual invasive disease.
The prognosis for patients who experience pCR is excellent and equivalent to those with
other breast cancer types who experience pCR. However, patients with TNBC who did
not experience pCR with the same chemotherapy have a poorer prognosis.6 In the pursuit
of identifying specific targeted therapies for TNBC, preclinical studies have recently
identified a few potential molecular targets such as epidermal growth factor receptor
(EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2); however, drug
candidates developed for these targets have underperformed at some point during their
clinical testing.5
Therefore, it is important to find effective treatments for TNBC. A better
understanding of the biology of TNBC will aid in identifying new molecules for
specifically targeting this disease. Molecular targets such as protein and genes have been
explored for early detection and treatment of TNBC without much success; however,
recently metabolites are being examined as an alternative and promising approach.
Cancer metabolic profiling enables identification of small-molecule metabolites in
biofluids and tissues that are sensitive to altered pathology of stimuli including disease
processes. Small molecule metabolites in biological samples such as blood, urine and
tissues have been examined using the powerful analytical techniques of nuclear magnetic
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resonance (NMR) and mass spectrometry (MS) and their combination with multivariate
statistical methods.7 Since these metabolites are sensitive to subtle differences in
pathological status, metabolites profiling may identify altered pathways and key enzymes
that could be targeted therapeutically.
In this study, we used a metabolomics approach to identify altered small-molecule
metabolites in TNBC. Intact cancer tissue samples (n=47) and normal adjacent tissue
(n=35) from 47 patients (30 African Americans, 17 Caucasian; normal adjacent 18
African Americans, 17 Caucasian) were obtained before neoadjuvant chemotherapy, and
were studied using high resolution magic angle spinning (HR-MAS) 1H-NMR and
multivariate statistics methods.

4.2 Materials and Methods

4.2.1 Chemicals and Patients Samples
Deuterium oxide (D2O, 99.9% D) was purchased from Cambridge Isotope
Laboratories, Inc. (Andover, MA).
A total of 82 human breast tissue samples (tumor and normal adjacent) were
collected from patients operated on at the Indiana University School of Medicine
Teaching Hospitals, Indianapolis IN, the University of Chicago, Chicago, IL and Arnett
Clinic in Lafayette, IN. Samples were frozen in liquid nitrogen prior to storage and
shipping to Purdue University for analysis.
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4.2.2 Sample Preparation
Frozen tissue samples were removed from their Eppendorf storage tubes using
tweezers, placed in a petri dish and kept on dry ice during the preparation. Tissues
samples were cut into an appropriate size, with weights between 11.4 and 22.4 mg, such
that they could fit into an HR-MAS NMR sample tube for analysis. To provide a fieldfrequency lock and for air removal 50l D2O was also transferred into each sample tube,
and then into the HR-MAS rotor and analysis.

4.3 NMR Experiments and Data Processing

4.3.1 NMR Experiments
1D 1H NMR experiments on the tissue samples were performed on a Bruker
Avance-III-800 spectrometer equipped with an HR-MAS probe. NMR data were
acquired using the 1D CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence with water
presaturation and the following parameters: number of scan=128; number of dummy
scans=16; number of time domain points =32K; spectral width=15.24 ppm; relaxation
delay=2 sec; acquisition time=1.34 sec; number of CPMG 180° pulses=400.

4.3.2 Data Processing and Statistics
After acquisition, the NMR data were Fourier transformed after apodization, and
the spectra were then phased, baseline corrected and referenced to the lipid peak δ=0.909
ppm using Bruker Topspin 3.0 software. The data were then binned to 4K buckets of
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equal width (0.0034 ppm) to minimize errors due to any fluctuations of chemical shifts
arising from pH or ion concentration variations using MestReNova 7.0 software. The
resulting data generated from MestReNova were transferred into Excel (Microsoft Office
Excel 2011). Spectral regions within the range of 0 to 9.0 ppm were used for the analysis
after removing the residual water peak in the range of 4.5 to 5.0 ppm. To identify
significantly different spectral bins for each metabolite between tumors and normal
adjacent, the unpaired Student's t-test was used. P-values ≤ 0.05 were considered to be
statistically significant. The binned NMR data were imported into Matlab (R2008a,
Mathworks, Natick, MA) installed with a PLS-DA toolbox (version 4.1, Eigenvector
Research, Inc., Wenatchee, WA) to classify tumor and normal adjacent groups. The R
statistical package (version 3.0.0) was used to generate box-and-whisker plots and
receiver operating characteristics (ROC) curves.

4.4 Results

4.4.1 Biomarker Discovery and Evaluation
Clinicopathological characteristics of patients and samples are summarized and
listed in Table 4.1. Representative HR-MAS NMR spectra of the 82 breast tissue samples
(47 tumors and 35 normal adjacent) are shown in Figure 4.1. The 29 metabolites
considered for multivariate classification models are listed in the Table 4.2 and indicated
in Figure 4.1.
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4.4.1.1 Effect of Age and Race
Supervised multivariate statistics using partial least squares discriminant analysis
(PLS-DA) models were developed to evaluate the combination of potential biomarker
candidates. The 29 metabolites in Table 4.2 were selected as the variables to build the
PLS-DA model. Leave-one-out cross-validation was performed to obtain the best model
and avoid over-fitting. Metabolites with p<0.05 are listed in Table 4.3 for tumor vs.
adjacent normal tissue for all ages, age>50, and age<50.. The PLS-DA score plots
derived from tumor versus normal adjacent tissue for all ages, age>50, and age<50 are
shown in Figure 4.2A, 4.2B, and 4.2C, respectively. Box-and-whisker plots for
metabolites with p<0.05 for the older and younger age groups are shown in Figure 4.3
and 4.4, respectively.

4.4.1.2 Effect of Estrogen Receptor Status
To study the effect of estrogen status on the breast cancer metabolite profile, PLSDA was again used to build a multivariate model to evaluate the combination of potential
biomarker candidates. To build the PLS-DA model the 29 metabolites in Table 4.2 were
again selected as the variables. Leave-one-out cross-validation was done to obtain the
best model and avoid over-fitting. Metabolites with p<0.05 are listed in Tables 4.5 and
4.6 for ER-negative and ER-positive tissue samples, respectively. The PLS-DA score
plots of tumor versus normal adjacent ER-negative and ER-positive tissue samples are
shown as in Figure 4.5A and 4.5B, respectively. Box-and-whisker plots are shown for the
metabolites with p<0.05 for both groups in Figure 4.6 and 4.7, respectively.
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For a better understanding of the effect of estrogen receptor status on the
metabolic profiles of African Americans and Caucasians, PLS-DA models consisting of
all the metabolites in Table 4.2 was constructed to compare tumor versus normal adjacent
tissues. Figure 4.8A and 4.8B are the PLS-DA metabolite profile score plots for African
Americans with ER-negative and ER-positive, respectively. Figure 4.8C and 4.8D show
ROC curves generated from the PLS-DA models of Figure 4.8A and 4.8B, respectively.
Box and whisker plots of the relative levels of metabolites with p<0.05 for ER-negative
and ER-positive African American women are shown in Figures 4.9 and 4.10,
respectively.
Uridine was the only metabolite in the group of ER-positive Caucasian women
with a p<0.05 (p = 1.06*10-2 ); no significant p-value for ER-negative Caucasian women
was observed. The box and whisker plot for uridine in tissue samples from ER-positive
Caucasian women is shown in Figure 4.111.

4.5 Discussion
The feasibility of HR-MAS NMR spectroscopy of breast tissue was investigated
to distinguish the metabolic differences between tumor and normal adjacent tissue
classified based on estrogen receptor status, age and race. HR-MAS NMR has been used
before in several cancer studies including colon, brain, prostate and breast cancer.8-11 In
this study, we investigated this technique to be used as an adjunct tool for differentiation
of tumor from normal adjacent breast tissue. Based on our results, we believe this
methodology, when combined with multivariate statistical analysis, has the potential for
use as a powerful complementary tool to the current clinical histopathological methods
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for better diagnosis and prognosis of breast cancer. This method is fairly fast, and
therefore could be used to quickly assess tissue samples around the time of surgery; since
NMR is nondestructive technique, the same sample can be used later for histopathology.
Our results showed that more metabolites change significantly when comparing
tumor to normal adjacent in women with ages above 50 compared to those below 50
years old. Myo-inositol and phosphocholine were significantly (p<0.05) increased in
tumor compare to normal adjacent tissues in both age groups. Choline, lactate, glutamate,
taurine, methionine, alanine, threonine, glycine, tyrosine, ATP (adenosine triphosphate),
glutathione, unsaturated lipid, lipid, valine, phenyalanine, glutamine, and α-glucose were
significantly altered for patients above 50 years old. However, for patients below 50
years old only uridine in addition to myo-inositol and phosphocholine was changed.
Data from Caucasian and African American women were also studied separately.
For Caucasians, most metabolites were not changed significantly whereas they were for
African Americans. These results could be affected by the sample collection methods.
Samples obtained from the University of Chicago mainly belonged to African Americans,
and thus this set was most likely consistent.
Estrogen receptor (ER) refers to a group cytoplasmic proteins existing in normal
estrogen target tissues such as uterus and breast. The ER status in invasive carcinomas is
very important for breast cancer prognosis. Studies show that women with ER-positive
tumors generally have a better prognosis.12,13 Moreover, in addition to the differences in
morphology, ER-positive and ER-negative tumor tissues they have different metabolite
profiles due differences in their altered metabolic pathways.14-16 Glutathion, myo-inositol,
taurine and lactate were significantly altered in tumor compare to normal adjacent tissues.
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Our results show that fewer metabolites change concentration in tumor compared to
normal adjacent tissues for ER-negative patients. Signals from lipid (0.909 ppm),
unsaturated lipid (5.333ppm) and α-glucose decreased in ER-negative tumors , the rest of
the metabolites shown in Figure 4.6 and 4.7 for ER-negative and positive patients,
respectively, were increased in tumor compare to normal adjacent tissue samples.
Results from comparing metabolite p-values between races showed that these
changes mostly occurred between African Americans. Uridine was the only metabolite
that changed significantly (p<0.05) among ER-positive Caucasians. Lactate, taurine and
glutathione were elevated in tumor for both ER-positive and ER-negative Caucasians.
However, among African Americans, glutathione was just changed significantly in the
ER-positive group (p <0.05). Glutathione is an intracellular antioxidant, and plays an
important role in cellular defense.17 Perry et al. also reported that glutathione levels were
elevated in breast cancer tumor tissue compared to normal tissue.18 Previous studies have
also showed that taurine and lactate are elevated in breast cancer tumors,19,20 and our
study agrees with these results, especially for women above age 50.
Uridine was elevated in tumors among ER-positive Caucasians below 50;
however, our results do not support previous studies on human breast cancer tumors that
showed an increase in the activity of Uridine phosphorylase (UPase).21,22 UPase is the
enzyme responsible for the reversible phosphorolysis of uridine to uracil. Therefore,
based on the previous results uridine concentration should be lower in tumor tissues
compared to normal adjacent.
Higher concentrations of choline and phosphocholine in breast cancer tumors
have been reported by a number of studies.23-26 Eliyahu et al. showed elevated levels of
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phosphocholine in breast cancer cells occurs as more choline is transported into the cells.
The activity of intracellular choline kinase increases several fold above that of CTP:PCho
cytidylyltransferase, and converts phosphocholine to cytidyldiphosphate-choline (CDPcholine).26 We did not find significant change in the intensity level of these two
metabolites for all patients with ER-negative tumors. However, for African Americans
with ER-negative tumors, we did see a statistically significant change for choline. A
study by Sitter et al. showed that the ratio of phosphocholine to choline is lower in ERnegative compare to ER-positive tumors.25 A study by Shin et al. using Magnetic
Resonance (MR) spectroscopy showed significant differences in the total choline
compounds between ER-positive and ER-negative (p=0.007), as did a study by Choi et
al. using HR-MAS. But our results was not in agreement with their results (p=0.34 for
choline and p=0.74 for phosphocholine).27,28 Likewise, several studies also indicated no
significant change between for choline compounds in ER-positive versus ER-negative
tumors (p=0.23).14,29
Findings from this study showed the intensity of numerous metabolites were
changed (p<0.05) in tumors from African American women compared to Caucasians, but
not significant change between them. Nevertheless, using PLS-DA results, and
considering all the metabolites listed in Table 4.2, not just low p-value metabolites,
showed that the HR-MAS analysis combined with multivariate statistical analysis could
completely distinguish ER-negative and ER-positive tumors from normal adjacent tissues
(see Figure 4.8). This result indicates that there are many smaller changes that when
combined help define the altered metabolism observed in breast tumors.
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The approach described in this study has some limitations. Since samples were
collected in 3 locations by different individuals, differences in the collection
methodology may have affected our results. It is possible that with additional number of
samples and a tighter control of sample collection, better results could be achieved,
especially for age<50 for both African Americans and Caucasians.
In conclusion, we showed that HR-MAS 1H NMR combined with multivariate
statistical analysis can be used as a powerful technique for identifying metabolic
differences between different tumor types.

Because of the effect called field

cancerization, characterizing the altered metabolite profiles of normal adjacent tissue is as
important as those for the tumor itself.30 This effect has been previously confirmed by
several studies.31,32 Results from this study show a wide variation in the metabolite levels
for tumors whereas the distribution of metabolites in normal adjacent tissue samples are
much narrower. Further prospective studies with more number of samples especially for
ages below 50 are needed to identify out the differences between ages in different
hormone receptor status and races.
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Table 4.1 Clinicopathological characteristics of women with invasive breast cancer.
Patient Characteristics
Total Patients

Number
47

African American women

30 (T=30; N=18)

Caucasian women

17 (T=17; N=17)

Pathology
Invasive carcinoma grade I and DCIS

3

Invasive carcinoma grade II

10

Invasive carcinoma grade III

25

Unknown

9

Patient Age
<50

10

>50

37

African American women
<50

7

>50

23

Caucasian women
<50

3

>50

14

ER Status
ER-

18

ER+

29

African American women
ER-

13

ER+

17

Caucasian women

T: tumor.
N: Normal adjacent.
ER: Estrogen receptor

ER-

5

ER+

12
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Table. 4.2 Quantified metabolites used for multivariate classification models.
Number
1

Metabolite
Acetate

2

Alanine

3

Arginine/Lysine/ Leucine

4

Chemical Shifts
(ppm)

Number

Metabolite

Chemical Shifts
(ppm)

1.927

15

Lactate

4.124

1.479

16

Lipid 1

0.909493

1.786-1.649

17

Lipid 2

2.777

ATP

6.125

18

Methionine

2.648

5

α-glucose

5.238

19

Myo-inositol

3.536

6

β-glucose

4.652

20

Phenylalanine

7.448-7.298

7

Choline

3.21

21

Phosphocholine

3.229

8

Creatine

3.032

22

Taurine

3.431

9

Formate

8.411

23

Threonine

4.261
st

10

Glutamate

2.355

24

Tyrosine(1 peak)

6.891

11

Glutamine

2.455

25

Tyrosine(2nd peak)

7.189

12

Glutathione

2.561

26

Unsaturated lipid

5.333

13

Glycine

3.567

27

Uridine

5.907

14

Isobutyrate

1.146

28

Valine

1.048
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Table. 4.3 Metabolites significantly (p<0.05) expressed between tumor and
adjacent normal tissues.
Metabbolites

T vs. N
(all ages)

Metabbolites

myo-inositol

1.78E-04

choline

T vs. N
(above 50)
2.40E-04

Metabbolites
uridine

T vs. N
(below 50)
2.17E-02

taurine

5.50E-04

lactate

2.69E-04

myo-inositol

3.99E-02

lactate

6.49E-04

glutamate

7.84E-04

phosphocholine

4.87E-02

phosphocholine

8.82E-04

myo-inositol

1.43E-03

glutathione

2.57E-03

taurine

3.43E-03

glutamine

4.67E-03

methionine

4.00E-03

ATP

6.22E-03

alanine

4.19E-03

glutamate

8.76E-03

phosphocholine

4.89E-03

choline

1.15E-02

threonine

6.50E-03

glycine

3.21E-02

glycine

6.90E-03

alanine

3.40E-02

tyrosine 2

1.15E-02

uridine

3.42E-02

tyrosine 1

1.16E-02

tyrosine 1

4.06E-02

ATP

1.17E-02

creatine

4.26E-02

glutathione

1.21E-02

tyrosine 2

4.60E-02

unsaturated lipid

1.23E-02

T: tumor
N: normal adjacent

lipid

1.45E-02

valine

1.53E-02

phenyalanine

1.64E-02

glutamine

2.31E-02

α-glucose

4.43E-02
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Table 4.4 Metabolites significantly expressed (P<0.05) in African American women:
tumors vs. adjacent normal.
Metabolites

Tumor African Americans vs. African American normal adjacent

lactate

6.90E-04

myo-inositol

1.15E-03

choline

1.16E-03

glutamate

1.21E-03

l-methionine

2.49E-03

taurine

3.82E-03

Alanine

4.52E-03

tyrosine 1

4.86E-03

glycine

5.27E-03

phosphcholine

5.53E-03

ATP

8.01E-03

tyrosine 2

8.13E-03

threonine

8.20E-03

lysine, leucine, arginine

8.74E-03

valine

1.08E-02

phenylalanine

1.15E-02

unsaturated lipid

1.29E-02

lipid

1.93E-02

glutamine

2.00E-02

glutathione

2.59E-02
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Table. 4.5 Metabolites differentially expressed (P<0.05) in ER-negative samples (tumor
vs. adjacent normal) regardless of race.

Metabolites

ER- tumor vs. ER- normal adjacent

unsaturated lipid

7.60E-03

lipid

1.14E-02

myo-inositol

1.34E-02

glutathione

1.83E-02

taurine

1.96E-02

α-glucose

2.02E-02

ATP

2.62E-02

lactate

3.40E-02

creatine

4.59E-02

Table. 4.6 Metabolites significantly expressed (P<0.05) in ER-positive samples (Tumors
vs. adjacent normal) regardless of race

Metabolites

ER+ tumor vs. ER+ normal adjacent

lactate

2.75E-03

choline

4.61E-03

phosphcholine

6.94E-03

myo-inositol

6.96E-03

glutamate

8.01E-03

methionine

8.21E-03

threonine

1.20E-02

taurine

1.49E-02

uridine

1.64E-02

Alanine

2.17E-02

glutamine

2.70E-02

glutathione

3.07E-02

glycine

3.29E-02

valine

4.51E-02

tyrosine 2

4.57E-02
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Table. 4.7 Metabolites significantly altered (P<0.05) in ER negative African American
women: tumor vs. adjacent normal tissues.
Metabolites

ER- tumor vs. ER- normal adjacent

unsaturated lipid

6.79E-03

a-glucose

7.97E-03

lipid

9.95E-03

lactate

2.04E-02

glycinne

2.17E-02

threonine

2.20E-02

Alanine

2.32E-02

glutamate

2.38E-02

glutathione

2.62E-02

taurine

2.84E-02

choline

2.90E-02

tyrosine 2

2.97E-02

tyrosine 1

3.27E-02

ATP

3.55E-02

valine

3.61E-02

Table. 4.8 Metabolites differentially altered (P<0.05) in ER-positive African Americans:
tumor vs. adjacent normal.
Metabolites
myoinositol

ER+ tumor vs. ER+ normal adjacent
6.79E-03

phosphcholine

9.09E-03

choline

1.91E-02

lactate

1.96E-02

methionine

2.28E-02

glutamate

2.69E-02

taurine

3.97E-02

L-lysine, L-leucine, arginine

4.08E-02

tyrosine 1

4.32E-02

107

A

B

Figure 4.1 Typical HR-MAS tissue spectra from (A) normal adjacent and (B, C, and D)
tumor breast cancer tissues.

tyrosine

tyrosine

phenylalanine

phenylalanine

Figure 4.1, continued
α-glucose

D
unsaturated lipid

lactate

isobutyrate
valine
isoleucine
valine
leucine

alanine

glutamate

choline

lysine/leucine/arginine

acetate
arginine

methionine

glutathione
glutamine
glutamate

methionine

lipid

creatine

taurine

myo-inositol
taurine

threonine

β-glucose

lipid

lipid

lactate

phosphocholine

glycine

C

uridines

ATP

uridines

formate
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p

Samples/Scores Plot of data

A

0.6
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Figure 4.8 Results of the PLS-DA model using the 29 metabolites for African Americans:
(A) ER-negative samples and (B) ER-positive samples. ROC curves using the crossvalidated predicted class values for African Americans: (C) ER-negative samples and (D)
ER-positive samples.

8.0e+09

choline

1.0e+10
0.0e+00

Tumor

Normal adjacent

threonine

8.0e+08
6.0e+08
4.0e+08
0.0e+00

2.0e+08

2e+09
0e+00

Normal adjacent

Normal
N
ladjacent
dj
t

5.0e+09

glycine

4e+09

1.0e+10

Tumor

Tumor
T

1.2e+09

2e+08
0e+00

Normal adjacent

6e+09

1.5e+10

taurine

5.0e+09
0.0e+00

Tumor

Normal adjacent

8e+09

Tumor

2.0e+10

0.0e+00

5.0e+09

4e+08

1.0e+10

6e+08

8e+08

glutathione

0.0e+00

Normal adjacent

1.5e+10

1e+09

Tumor

1.0e+09

0.0e+00

5.0e+08

4.0e+09

1.0e+09

1.0e+12
5.0e+11

Normal adjacent

glutamate

1.5e+10

0e+00

Tumor

alanine

1.2e+10

2.0e+09

valine

1.5e+09

1.5e+12

lipid

2.5e+09

118

Tumor

Normal adjacent

Tumor

Normal adjacent

Figure 4.9 Box-and-whisker plots of metabolites with p<0.05 illustrating discrimination
between tumor and normal adjacent tissues for ER-negative African Americans.
Horizontal line in the middle portion of the box indicates the median. Top and bottom
boundaries of boxes show the 75th and 25th percentiles, respectively. Upper and lower
whiskers show 95th and 5th percentiles, respectively. Open circles show outliers.

3e+11

1.0e+08 1.5e+08

4e+11

0.0e+00 5.0e+07

2e+11
1e+11
0e+00

Normal adjacent

tyrosine 2

lactate

3e+10
0e+00

0e+00

Normal adjacent

Normal adjacent

1e+10

2e+08

4e+08
2e+08
0e+00

Tumor

Tumor

2e+10

4e+08

6e+08

8e+08

tyrosine 1

Tumor

6e+08

Normal adjacent

4e+10

1.5e+10
1.0e+10
5.0e+09
e+00

Tumor

ATP

2.0e+08 2.5e+08

6e+11

unsaturated lipid

5e+11

2.0e+10

α-glucose

3.0e+08

119

Tumor

Normal adjacent

Figure 4.9, Continued.

Tumor

Normal adjacent

120

1.0e+10
0.0e+00

Normal adjacent

myo-insitol

Normal adjacent

5e+09
4e+09
3e+09
2e+09

Tumor

Tumor

Normal adjacent

tyrosine 1

0.0e+00

5.0e+08

1.0e+09

lactate

Normal adjacent

1.5e+09

Tumor

0e+00

0e+00

0e+00

1e+09

1e+09

1e+10

2e+09

3e+09

2e+10

4e+09

5e+09

3e+10

taurine

Tumor

7e+09

Normal adjacent

4e+10

phosphocholine

6e+09

Tumor

Normal adjacent

6e+09

0e+00

2e+08

5.0e+09

4e+08

1.0e+10
5.0e+09

Tumor

7e+09

0.0e+00

choline

1.5e+10

8e+08

methionine

6e+08

1.5e+10

glutamate

Tumor

Normal adjacent

Figure 4.10 Box-and-whisker plots of metabolites with p<0.05 illustrating discrimination
between tumor and normal adjacent tissues for ER-positive African Americans.
Horizontal line in the middle portion of the box indicates the median. Top and bottom
boundaries of boxes show the 75th and 25th percentiles, respectively. Upper and lower
whiskers show 95th and 5th percentiles, respectively. Open circles show outliers.

2.0e+08 4.0e+08 6.0e+08 8.0e+08 1.0e+09 1.2e+09 1.4e+09

121

uridine

Tumor

Normal adjacent

Figure 4.11 Box-and-whisker plots of uridine illustrating discrimination between tumor
and normal adjacent tissues for ER-positive Caucasians. Horizontal line in the middle
portion of the box indicates the median. Top and bottom boundaries of boxes show the
75th and 25th percentiles, respectively. Upper and lower whiskers show 95th and 5th
percentiles, respectively. Open circles show outliers.

VITA

122

VITA

Fariba Tayyari was born in Iran to Ebtehaj Haghighi and Faramarz Tayyari. She
received the degree of Bachelor of Science from Ferdowsi University, Mashhad, Iran, in
2003. She entered the Graduate School in the Department of Chemistry at Ball State
University, Muncie, IN, in 2006, under the supervision of Dr. Robert Sammelson, and
received a Master's of Science degree in July 2008. Fariba started her Ph.D. studies in the
Department of Chemistry at Purdue University, West Lafayette, IN, in 2008. While at
Purdue University she joined Professor Daniel Raftery’s research group where she started
doing research on NMR-based metabolomics.

PUBLICATION6

123

Anal. Chem. 2010, 82, 8983–8990

Quantitative Analysis of Blood Plasma Metabolites
Using Isotope Enhanced NMR Methods
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NMR spectroscopy is a powerful analytical tool for both
qualitative and quantitative analysis. However, accurate
quantitative analysis in complex ﬂuids such as human
blood plasma is challenging, and analysis using onedimensional NMR is limited by signal overlap. It is
impractical to use heteronuclear experiments involving
natural abundance 13C on a routine basis due to low
sensitivity, despite their improved resolution. Focusing
on circumventing such bottlenecks, this study demonstrates the utility of a combination of isotope enhanced NMR experiments to analyze metabolites in
human blood plasma. 1H-15N HSQC and 1H-13C
HSQC experiments on the isotope tagged samples
combined with the conventional 1H one-dimensional
and 1H-1H TOCSY experiments provide quantitative
information on a large number of metabolites in
plasma. The methods were ﬁrst tested on a mixture of
28 synthetic analogues of metabolites commonly present
in human blood; 27 metabolites in a standard NIST
(National Institute of Standards and Technology) human blood plasma were then identiﬁed and quantiﬁed
with an average coefﬁcient of variation of 2.4% for 17
metabolites and 5.6% when all the metabolites were
considered. Carboxylic acids and amines represent a
majority of the metabolites in body ﬂuids, and their
analysis by isotope tagging enables a signiﬁcant enhancement of the metabolic pool for biomarker discovery applications. Improved sensitivity and resolution of NMR experiments imparted by 15N and 13C
isotope tagging are attractive for both the enhancement
of the detectable metabolic pool and accurate analysis
of plasma metabolites. The approach can be easily
extended to many additional metabolites in almost any
biological mixture.
Nuclear magnetic resonance (NMR) spectroscopy is increasingly used in metabolomics for the analyses of multiple metabolites
in bioﬂuids and tissues. Metabolomics promises a number of
important applications in biomedicine including a more detailed
understanding of biological processes, the discovery of the
biomarkers associated with numerous diseases, pharmaceutical
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Purdue University.
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development, and toxicology.1-6 It is increasingly recognized that
because of its high reproducibility and quantitative nature, NMR
is a very attractive analytical tool. In particular, the improved
resolution of two-dimensional (2D) NMR methods is considered
very useful for metabolomics applications.7-11 However, a major
drawback of 2D NMR is that the cross-peak volume in the
spectrum is inﬂuenced by numerous experimental or intrinsic
parameters including the nonuniform excitation proﬁle of the radio
frequency pulses, number and duration of the pulses, interpulse
delays, relaxation times, and the magnitude of indirect spin-spin
couplings. The high sensitivity of peak intensities (or volumes)
to these parameters has limited the use of 2D (particularly 1H
homonuclear 2D) experiments for quantitative analysis in
metabolomics.
To overcome the limitations of quantitation and to improve
the analysis, new higher resolution 2D approaches utilizing
1
H-13C heteronuclear 2D experiments (HSQC) have been
proposed.12,13 One approach is to utilize the information from
2D 1H-13C NMR spectra of standard compounds obtained
under identical conditions and relate the peak heights in the
samples to standard mixtures;12 another is to utilize calibration
curves obtained using 1H-13C HSQC spectra for individual
metabolites to determine the metabolite concentrations.13 Most
recently, a more general approach that does not require
(1) Nicholson, J. K.; Lindon, J. C.; Holmes, E. Xenobiotica 1999, 29, 1181–
1189.
(2) Clayton, T. A.; Lindon, J. C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton,
G.; Provost, J. P.; Le Net, J. L.; Baker, D.; Walley, R. J.; Everett, J. R.;
Nicholson, J. K. Nature 2006, 440, 1073–1077.
(3) Beckonert, O.; Keun, H. C.; Ebbels, T. M.; Bundy, J.; Holmes, E.; Lindon,
J. C.; Nicholson, J. K. Nat. Protoc. 2007, 2 (11), 2692–2703.
(4) Pan, Z.; Raftery, D. Anal. Bioanal. Chem. 2007, 387, 525–527.
(5) Nagana Gowda, G. A.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery,
D. Expert Rev. Mol. Diagn. 2008, 8, 617–633.
(6) Holmes, E.; Wilson, I. D.; Nicholson, J. K. Cell 2008, 134 (5), 714–717.
(7) Dumas, M-.E.; Canlet, C.; Andre, F.; Vercauteren, J.; Paris, A. Anal. Chem.
2002, 74, 2261–2273.
(8) Tang, H.; Wang, Y.; Nicholson, J. K.; Lindon, J. C. Anal. Biochem. 2004,
325, 260–272.
(9) Dumas, M-.E.; Canlet, C. J. Proteome Res. 2005, 4, 1493–1502.
(10) Xi, Y.; de Ropp, J. S.; Viant, M. R.; Woodruff, D. L.; Yu, P. Metabolomics
2006, 2, 221–233.
(11) Fonville, J. M.; Maher, A. D.; Coen, M.; Holmes, E.; Lindon, J. C.; Nicholson,
J. K. Anal. Chem. 2010, 82, 1811–1821.
(12) Lewis, I. A.; Schommer, S. C.; Hodis, B.; Robb, K. A.; Tonelli, M.; Westler,
W. M.; Sussman, M. R.; Markley, J. L. Anal. Chem. 2007, 79 (24), 9385–
9390.
(13) Gronwald, W.; Klein, M. S.; Kaspar, H.; Fagerer, S. R.; Nürnberger, N.;
Dettmer, K.; Bertsch, T.; Oefner, P. J. Anal. Chem. 2008, 80 (23), 9288–
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measurements of standard compounds was proposed.14 This
method utilizes correction factors derived theoretically from
the solution of the Bloch equations and the analysis of product
operator formalism incorporating longitudinal (T1) and transverse (T2) relaxation parameters, 1H-13C heteronuclear Jcoupling, and various delays used in the pulse sequence.
A major drawback of the use of the 1H-13C HSQC experiment
for quantitative analysis is the poor signal to noise ratio arising
from low metabolite concentration and natural abundance of
13
C (1.1% natural abundance). To compensate this limitation,
unusually long acquisition times (nearly 10 h or more) are
required since the NMR sensitivity scales with the square-root
of the number of scans. Moreover, although 1H-13C HSQC
greatly enhances resolution when compared with 1D NMR,
given the complexity of the biological samples, the resolution
obtainable from a single 2D experiment is not always adequate
for analyzing a large number of metabolites.
In the present study, with the idea of circumventing the
drawbacks of resolution and sensitivity, we utilize a combination
of isotope tagging approaches and 2D NMR methods to accurately
analyze human plasma metabolites. A number of the most
common metabolites in blood plasma were quantiﬁed using this
approach after validating the experimental protocols using a
mixture of synthetic compounds. Metabolites containing carboxyl
and amino groups were tagged with 15N and 13C, respectively,
before detection by 2D NMR. We have recently shown the
proof-of-principle approaches to introduce isotope tags using
simple chemical derivatization methods and that the NMR
spectra of the tagged metabolites improve both resolution and
sensitivity.15-18 The combination of advanced isotope tagging
methods with conventional 1D and 2D NMR methods as described
in the present study enables the quantitative analysis of a large
number of metabolites in human blood on a routine basis.
EXPERIMENTAL SECTION
Chemicals and Blood Plasma. Twenty-eight metabolite
standards (Table 1), 4,4-dimethyl-4-silapentane-1-sulfonic acid
(DSS), maleic acid, ethanolamine (all from Sigma-Aldrich, St.
Louis, MO), 4-(4,6-dimethoxy [1,3,5] triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM; Acros, Geel, Belgium), 13C-formic
acid (Cambridge Isotope Laboratories, Andover, MA), 15Nethanolamine, N,N-dicyclohexylcarbodiimide, and N-hydroxysuccinimide (Sigma-Aldrich) were used without further puriﬁcation. An ultrapure primary quantitative standard, tris(hydroxymethyl)aminomethane, (99.9%) was obtained from
Mallinckrodt Baker Inc. (Phillipsburg, NJ). Human blood
plasma (10 × 1 mL) was procured from the National Institute
of Standards and Technology (NIST, Gaithersburg, MD).
Frozen plasma samples were transported to Purdue University
under dry ice and stored at -80 °C until used for the analysis.
(14) Rai, R. K.; Tripathi, P.; Sinha, N. Anal. Chem. 2009, 81 (24), 10232–10238.
(15) Shanaiah, N.; Desilva, A.; Nagana Gowda, G. A.; Raftery, M. A.; Hainline,
B. E.; Raftery, D. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (28), 11540–
11544.
(16) DeSilva, M. A.; Shanaiah, N.; Nagana Gowda, G. A.; Rosa-Pérez, K.; Hanson.,
B. A.; Raftery, D. Magn. Reson. Chem. 2009, 47, S74–S80.
(17) Ye, T.; Mo, H.; Shanaiah, N.; Nagana Gowda, G. A.; Zhang, S.; Raftery, D.
Anal. Chem. 2009, 81 (12), 4882–4888.
(18) Ye, T.; Zhang, S.; Mo, H.; Tayyari, F.; Nagana Gowda, G. A.; Raftery, D.
Anal. Chem. 2010, 82 (6), 2303–2309.
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Table 1. Synthetic Analogues of Metabolites Used for
the Quantitative Analyses of Human Plasma
Metabolites

serial
number

standard
compound

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

3-hydroxybutyrate
acetate
L-alanine
L-arginine
citrate
creatinine
formate
L-glutamic acid
L-glutamine
L-glycine
L-histidine
L-isoleucine
lactate
L-leucine
L-lysine
L-methionine
L-phenylalanine
L-proline
L-threonine
L-tryptophan
L-tyrosine
L-valine
succinate
betaine
4-hydroxy proline
L-serine
L-asparagine
taurine

actual NMR
estimated
calibrated
approximate blood
concentrations in
plasma
the mixture (μM)
concentrationsa (μM) used for spikingb
60
80
300
80
30
40
40
50
300
200
80
50
1000
80
100
20
70
100
100
30
80
200
10
50
50
100
40
30

59.2 ± 0.9
73.7 ± 1.1
287.1 ± 4.5
90.1 ± 1.4
28.1 ± 0.4
31.6 ± 0.6
32.5 ± 0.5
53.8 ± 0.3
292.1 ± 2.8
172.6 ± 2.7
83.7 ± 0.6
50.7 ± 0.2
959.5 ± 15.1
80.7 ± 1.2
75.3 ± 2.3
19.2 ± 0.03
71.1 ± 1.1
93.3 ± 1.5
90.0 ± 1.9
29.1 ± 0.4
80.9 ± 0.3
183.2 ± 1.5
9.9 ± 0.1
44.6 ± 0.7
53.4 ± 0.8
93.3 ± 0.7
43.9 ± 0.7
27.7 ± 0.1

a
Obtained from the combination of database search and comparison
of the relative peak integrals in the NMR spectra. b The errors are
standard deviations from two measurements.

Calibration of the Standard Solutions. Twenty-eight metabolites that commonly occur in human blood plasma were
selected on the basis of entries in the human metabolite database
(HMDB)19 and the analysis of isotope labeled 1H-13C HSQC and
1
H-15N HSQC spectra, as well as 1D and 2D 1H-1H TOCSY
spectra of a human plasma sample. Stock solutions (20 mM)
for the synthetic analogues of all these 28 metabolites (Supplementary Table S1, Supporting Information) and internal standards, DSS (5 mM), maleic acid (20 mM) and ethanolamine (20
mM), were prepared. The concentration of the DSS solution was
calibrated using 1H NMR against a primary stoichiometric
standard, tris(hydroxymethyl)aminomethane (22.4 mM), prepared in the lab. The calibrated DSS solution was then used
to calibrate all other standard solutions. Brieﬂy, solutions of
the synthetic analogues of the 28 metabolites and internal
standards were divided into ﬁve groups as shown in Supplementary Table S2, Supporting Information. The grouping of
samples in Table S2 was such that the 1H NMR peaks for at least
one proton from each compound in the group were isolated
for the measurement of the peak integral. For each group, the
one-dimensional (1D) 1H NMR spectrum was recorded, and
(19) Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.; Young, N.; Cheng,
D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.;
Coutouly, M. A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard,
P.; Amegbey, G.; Block, D.; Hau, D. D.; Wagner, J.; Miniaci, J.; Clements,
M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G. E.; Macinnis, G. D.;
Weljie, A. M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner, R.; Li, L.;
Marrie, T.; Sykes, B. D.; Vogel, H. J.; Querengesser, L. Nucleic Acids Res.
2007, 35 (Database issue), D521–D526.
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on the basis of the integrated area of the isolated peaks with
reference to DSS, exact concentrations of the standard solutions
were determined (Supplementary Table S1, Supporting Information).
Mixture Analysis. A mixture of the 28 synthetic analogues
of the metabolites was prepared using the stock solutions such
that the ﬁnal concentration of each standard compound was
matched approximately to its expected concentration in human
blood plasma19 (Table 1). From this mixture, three identical sets
of samples (Set 1, Set 2, and Set 3) were prepared (see Supporting
Information; Flow Diagram 1); each set consisted of four solutions,
2 × 500 μL and 2 × 1000 μL of the mixture. All solutions were
then dried under vacuum. To the samples from Set 1, maleic acid
solution (92 nmol) was added as an internal reference and the
solutions were diluted to 500 μL using doubly distilled water. The
carboxylic acid class of metabolites was then tagged with 15Nlabeled ethanolamine following the established procedure17
(see Supporting Information). To each sample from Set 2,
ethanolamine solution (200 nmol) was added as an internal
reference and the solution was diluted to 500 μL using doubly
distilled water. Amines and amino acids were subjected to 13C
isotope tagging using a 13C-formic acid reaction following the
established procedure18 (see Supporting Information). Finally,
to the samples from Set 3, DSS (9.44 nmol) was added as an
internal reference and reconstituted in 560 μL of phosphate buffer
(pH ) 7.4) in D2O and transferred to 5 mm NMR tubes for 1D
and 1H-1H 2D TOCSY NMR experiments.
Isotope Tagging of Plasma Metabolites. Cold methanol (4
°C; 9.6 mL) was added to 4.8 mL of the NIST plasma, vortexed,
and then kept for 30 min at -20 °C. The precipitated protein pellet
was removed after centrifuging at 13 200 g for 10 min. The
supernatant was divided into 12 equal parts and divided into three
groups, each group consisting of four samples (see Supporting
Information; Flow Diagram 2). In each group, two samples served
as controls and the remaining two were spiked with 400 μL of
the stock solution mixture of 28 synthetic samples. All three
groups of samples were then dried in vacuum. One group was
used to label metabolites containing carboxyl groups with 15Nethanolamine, and the second group was used to label
metabolites containing amino groups with 13C-formic acid, after
the addition of internal standards, either maleic acid or
ethanolamine, appropriately. Identical procedures were used
for isotope tagging the plasma metabolites. To the third group
of samples, DSS (9.44 nmol) was added as an internal reference
and reconstituted in 560 μL of phosphate buffer (pH ) 7.4) in
D2O. Samples from all the three preparations were transferred
to 5 mm NMR tubes after adjusting the pH and solution
conditions as described earlier for the mixture of standards.
NMR Experiments. NMR experiments were performed at 298
K on a Bruker Avance-III 800 MHz spectrometer equipped with
a room temperature 1H inverse detection Z-gradient probe or a
Bruker DRX-500 spectrometer equipped with a 1H inverse
detection Z-gradient cryo-probe. 1D NMR experiments for the
ﬁve groups of standard samples (Supplementary Table S2,
Supporting Information), the mixture of 28 synthetic analogues,
and the plasma extracts were performed using a one pulse
sequence with residual water signal suppression by presaturation
during relaxation delay. Thirty-two scans with 64 k time domain

Figure 1. 2D spectra of mixtures of 28 synthetic compounds
obtained with or without isotope tagging: (a) 1H-15N HSQC spectrum
with15N tagging of carboxylic acids, (b)1H-13C HSQC spectrum with
13
C tagging of amines and amino acids, and (c) 1H-1H TOCSY
spectrum of the neat mixture. All the spectra were obtained on a 800
MHz spectrometer. The labeled peaks correspond to the numbered
metabolites in Table 1.

data points were collected with a sufﬁciently long recycle delay
(20 s) to ensure complete recovery of the magnetization between
scans. For the 15N isotope tagged samples, 1H-15N 2D HSQC
experiments were performed employing an INEPT (insensitive
nuclei enhanced by polarization transfer) transfer delay of 5.5
ms corresponding to a 1JNH of 90 Hz. Spectral widths of
approximately 10 kHz in the 1H and 5 kHz in the 15N
dimensions were used for the 800 MHz experiments. For 13C
Analytical Chemistry, Vol. 82, No. 21, November 1, 2010
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Figure 2. Concentration of 28 standard metabolites obtained by combining 2D NMR experiments with and without 15N or 13C tagging: (a)
obtained from 1H-15N HSQC NMR after 15N tagging; (b) obtained from 1H-13C HSQC NMR after 13C tagging, and (c) obtained from 1H-1H
TOCSY NMR of the neat mixture. The shaded bar on the right in each pair represents the actual concentration of the metabolite.

isotope tagged samples, sensitivity-enhanced 1H-13C 2D HSQC
experiments were performed employing an INEPT transfer
delay of 2.5 ms corresponding to a 1JC-H of 200 Hz. Spectral
widths of approximately 10 kHz for the 1H dimension and
600 Hz for 13C were used at 800 MHz. For both 1H-15N
HSQC and 1H-13C HSQC 2D experiments, 128 free induction
decays were collected along the indirect (t1) dimensions
using four transients per increment and a 2 or 3 s recycle
delay, resulting in a total acquisition time of 18 min for the
1
H-15N HSQC and 28 min for the 1H-13C HSQC. Phasesensitive data were obtained using echo-antiecho mode with
8986
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nitrogen (for 1H-15N HSQC) or carbon (for 1H-13C HSQC)
decoupling during acquisition (t2 dimension) using the GARP
(globally optimized alternating-phase rectangular pulses)
sequence. 1H-1H 2D TOCSY experiments were performed
on the neat (nonderivatized) samples with a spectral width
of 6 kHz (500 MHz) or 12 kHz (800 MHz) in both the
dimensions. The residual water signal was suppressed by
presaturation. Free induction decays (400) were collected
with t1 increments using eight transients per increment and
a 2 s recycle delay, resulting in a total acquisition time of
116 min (500 MHz) or 111 min (800 MHz).
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All 1D data were Fourier transformed with a 0.3 Hz line
broadening function. The 2D data were zero-ﬁlled to 1024 points
in the t1 dimension after forward linear prediction to 512 points
and Fourier-transformed after multiplying by a squared sinebell window function shifted typically by π/4 or π/2 along both
the dimensions. All NMR data were processed with Bruker
Topspin 2.0 on a Redhat Linux platform and Bruker XWINNMR
3.5 on a SGI/IRIX platform. An automatic baseline correction
using a polynomial of degree 5 was used to correct the baseline
in both 1D and 2D spectra.
Peaks in the 1D and 2D NMR spectra were assigned to various
metabolites on the basis of literature reports.17-19 Integrals for
well resolved peaks in the 1D and 2D spectra were obtained with
respect to the peak for the internal standard DSS, maleic acid or
ethanolamine. Integral limits for each peak in the 2D spectra were
selected such that the selected region encompassed the whole
peak and that no other peak interfered with the selection. Once
chosen for each type of 2D spectrum, the same sets of integral
limits were used for all other samples. Concentrations of the
plasma metabolites were determined by comparing the peak
integrals from the spectra obtained with and without spiking with
the synthetic analogues and also by directly comparing the peak
integrals of the plasma metabolites with those from the standards.
The accuracy, reproducibility, and errors were estimated from two
to eight measurements, depending on the detection of the resolved
peak for a particular metabolite in one or more types of spectra,
for both synthetic mixtures and plasma samples. The 1H-15N
HSQC, 1H-13C HSQC, and 1H-1H TOCSY experiments and
the data analyses were performed by independent persons.
Table 2. 1H,

13

C, and

RESULTS
The standard solutions of the synthetic analogues of the plasma
metabolites and internal standards (maleic acid and ethanolamine),
prepared on the basis of their weights, were calibrated using 1D
1
H NMR. The actual concentration of the standard solutions
prepared on the basis of the weight varies depending on the
purity and hygroscopic nature of the compounds, and hence,
it is important to calibrate the standard solutions especially for
accurate quantitative analysis. The DSS solution, which was
ﬁrst calibrated using a primary stoichiometric standard, tris(hydroxymethyl)aminomethane, was used for calibrating all
the standard solutions (Supplementary Table S2, Supporting
Information). The difference between the concentrations determined on the basis of sample weight and calibration using 1D
NMR varied as much as 10% for all but three metabolites, which
varied up to nearly 20% (Supplementary Table S1, Supporting
Information) due to hygroscopic nature of the metabolites or
sample impurities.
Analysis of Synthetic Metabolite Mixture. A mixture of 28
metabolites was analyzed using both 15N and 13C isotope tagging
approaches. Figure 1 shows 2D spectra of the mixture of 28
compounds with 15N and 13C isotope tagging, as well as without
tagging. The integrated 2D peak volumes were obtained and
then used to calculate the metabolite concentrations. Figure 2
shows the concentration of the compounds, thus, determined. As
can be seen in the ﬁgure, an excellent match between the
metabolite concentrations derived from NMR methods and the
actual values was obtained. Further, as shown in Supplementary

15

N Chemical Shifts of the Peaks Used in the Analysis of NIST Plasma Metabolites

experiment: 1H-15N HSQC
label

metabolite

2
3
5
8
10
11
17
19
20
21
22
24
25

acetate
L-alanine
citrate
L-glutamic acid
L-glycine
L-histidine
L-phenylalanine
L-threonine
L-tryptophan
L-tyrosine
L-valine
betaine
4-hydroxy proline

1

H (ppm)

experiment: 1H-13C HSQC
15

N (ppm)

8.01
8.23
8.04
8.21
8.12
8.25
8.13
8.28
8.03
8.18
8.30
8.57
8.26

label

120.93
113.70
122.62
115.58
114.78
116.42
117.19
117.52
116.90
117.25
118.43
124.28
116.74

3
10
11
12
18
19
20
22
25
26
27
28

experiment: 1H 1D NMR
label

metabolite

1
2
3
7
9
11
12
16
17
20
21
22
29

3-hydroxybutyrate
acetate
L-alanine
formate
L-glutamine
L-histidine
L-isoleucine
L-methionine
L-phenylalanine
L-tryptophan
L-tyrosine
L-valine
glucose

metabolite
L-alanine
L-glycine
L-histidine
L-isoleucine
L-proline
L-threonine
L-tryptophan
L-valine

4-hydroxy proline
L-serine
L-asparagine

taurine

1

H (ppm)

13

7.96
8.03
7.97
8.03
8.10
8.12
7.88
8.05
8.04
8.07
8.01
7.99

C (ppm)
163.40
164.15
163.56
163.81
163.10
164.12
163.51
163.88
165.21
163.92
163.57
164.23

experiment: 1H-1H TOCSY
1

H (ppm)

label

1.19
1.91
1.47
8.45
2.13
7.06
1.01
2.13
7.42
7.74
6.89
1.03
5.23

4
5
11
12
13
14
15
19
20
21
22

metabolite
L-arginine

citrate
L-histidine
L-isoleucine

lactate
L-leucine
L-lysine
L-threonine
L-tryptophan
L-tyrosine
L-valine

1

H (ppm) F2 dimension
1.68
2.65
7.07
3.66
1.32
0.95
3.02
3.57
7.53
6.90
3.60

1

H (ppm) F1 dimension
3.23
2.51
7.06
0.98
1.32
1.70
1.48
1.33
7.72
7.18
2.27
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Figure 4. Concentrations of metabolites in the NIST plasma obtained
using 1D/2D NMR experiments with and without isotope tagging: (a)
obtained from 1H-15N HSQC NMR after 15N tagging, (b) obtained
from 1H-13C HSQC NMR after 13C tagging, (c) obtained from 1H-1H
TOCSY NMR of neat plasma, and (d) obtained from 1D NMR of the
neat plasma sample.

Figure 3. 2D spectra of NIST plasma obtained with and without
isotope tagging: (a) 1H-15N HSQC spectrum obtained after 15N
tagging of carboxylic acids, (b)1H-13C HSQC spectrum obtained after
13
C tagging of amines and amino acids, and (c) 1H-1H TOCSY
spectrum of the neat mixture. All the spectra were obtained on an
800 MHz spectrometer. The labeled peaks correspond to the
numbered metabolites in Table 1.

Figure S1 (Supporting Information), a correlation of the NMR
derived values with the expected values showed a very good
agreement for all low and high concentration metabolites (R2 >
0.99).
Quantitation of Plasma Metabolites. The 1D 1H NMR
spectrum of the plasma sample obtained without isotope
labeling is highly complex, with only a relatively small number
of metabolite signals being isolated from other signals (Supple8988
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mentary Figure S2, Supporting Information). 2D HSQC spectra
of plasma samples tagged with 15N and 13C isotopes provide
resolved peaks for a much larger number of carboxylic acid
and amine class of metabolites. Figure 3 shows 2D spectra of
the plasma obtained with and without 15N or 13C tagging. The
2D TOCSY spectrum of the same plasma sample also provided
a number of well resolved peaks (Figure 3c). However, unlike
the HSQC spectra, the TOCSY spectrum showed a number of
redundant peaks for the same metabolite, which increases the
complexity of the spectrum.
Quantitation of the plasma metabolites followed an identical
procedure used for the determination of the concentrations of
metabolites in the synthetic mixture. The integrated peak areas/
volumes in the 1D/2D spectra of the neat and the spiked plasma
samples were obtained, and the metabolite concentrations were
determined. Twenty-seven metabolites that were identiﬁed in
human plasma were analyzed in duplicate measurements with and
without 15N and 13C isotope tagging. Figure 4 depicts the
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Table 3. NIST Plasma Metabolite Concentrations Obtained Using a Combination of NMR Experiments with or
without Isotope Tagging
label

metabolite

NIST plasma
concentration (μM)a

1
2
3
4
5
7
8
9
10
11
12
13
14
15

3-hydroxybutyratee
acetateb,e
b,c,e
L-alanine
d
L-arginine
b,d
citrate
formatee
b
L-glutamic acid
e
L-glutamine
b,c
L-glycine
b,c,d,e
L-histidine
c,d,e
L-isoleucine
lactated
d
L-leucine
d
L-lysine

99.3 ± 13.1
142.0 ± 3.0
279.4 ± 18.9
155.9 ± 16.0
40.1 ± 2.3
51.2 ± 2.1
69.3 ± 5.3
368.5 ± 2.3
204.5 ± 31.2
63.1 ± 5.7
48.2 ± 2.4
2403.6 ± 127.6
100.1 ± 0.1
190.8 ± 21.9

label
16
17
18
19
20
21
22
24
25
26
27
28
29

metabolite
e

L-methionine
b,e
L-phenylalanine
c
L-proline
b,c,d
L-threonine
b,c,d,e
L-tryptophan
b,d,e
L-tyrosine
b,c,d,e
L-valine

betaineb
4-hydroxy prolineb,c
c
L-serine
c
L-asparagine
taurinec
glucosee

NIST plasma
concentration (μM)a
16.6 ± 2.8
50.6 ± 3.8
127.6 ± 13.1
107.3 ± 16.7
45.9 ± 8.1
58.9 ± 7.2
159.7 ± 11.6
27.3 ± 2.8
11.5 ± 1.3
95.8 ± 15.0
33.4 ± 2.8
32.4 ± 0.8
8778.5 ± 62.8

a
The errors are standard deviations. b Obtained from 1H-15N HSQC. c Obtained from 1H-13C HSQC. d Obtained from 1H-1H TOCSY. e Obtained
from 1H 1D NMR. Two samples were used for each type of experiment resulting in two, four, six, or eight independent measurements for each
metabolite.

Figure 5. Comparison of the concentrations of (a) carboxylic acid
and (b) amino group containing metabolites in the NIST plasma
obtained with spiking (left bars) and without spiking (right bars) with
the standard compounds.

concentration of the metabolites, thus, determined. The 1H, 13C,
and 15N chemical shifts for the blood plasma metabolites
analyzed in this study are shown in Table 2, and the derived
concentrations using a combination of four different NMR
methods are shown in Table 3. Further, the concentration of the
carboxylic acid and amine class of metabolites were also determined by directly comparing the 2D peak integrals with those
for the corresponding standard compound. Comparison of the
metabolites concentration determined with and without spiking
is shown in Figure 5. Notably, the values determined from both
approaches agree well.
DISCUSSION
1
H NMR spectroscopy is an attractive tool for the quantitative analysis of multiple metabolites from intact biological

samples. Considering its ease of use, reproducibility, and highthroughput nature, 1D 1H NMR spectroscopy is often used for
metabolomics-based studies. However, it is challenging to
analyze the 1D NMR spectrum of plasma in an absolute
quantitative fashion as it contains a large number of overlapping
signals due to hundreds of metabolites present at variable
concentrations. The multiplicity of the signals due to J-coupling
makes 1D 1H NMR spectra of plasma particularly challenging.
The interference from macromolecules such as proteins and
lipids adds to the complexity and causes baseline distortions
in the spectra. Such overlap and baseline issues substantially
affect the accuracy of the quantitative analysis using 1D NMR.
To offset such limitations, a majority of the studies that use
1D NMR resort to comparisons of the relative intensities of
the 1D NMR signals between disease and healthy samples.
While the use of relaxation edited techniques such as the
Carr-Purcell-Meiboom-Gill (CPMG) experiment, serum/
plasma deproteinization, and line ﬁtting approaches signiﬁcantly
improves the analysis of metabolites,20 such methods are not
ideal. Diffusion-sensitized 1D NMR spectroscopy, which uses
data from two separate 1D experiments, one obtained using
low diffusion gradients and the other using high gradients to
suppress macromolecular background signals effectively, was
shown to be useful for the quantitative analysis of blood plasma
metabolites.21 However, spectral overlap still signiﬁcantly limits
the number of metabolites that can be analyzed.
2D NMR promises quantitative analysis of a large number of
metabolites on a routine basis. An important requirement is that
the cross-peaks in 2D spectra should be devoid of overlaps for
reliable quantitative results; however, this criterion is not often
met for a large number of metabolites by a single 2D experiment
due to the extremely high complexity of plasma. The advantage
of the new 2D NMR approaches used here is that the use
chemoselective isotope tags greatly reduces the complexity of the
spectra, since only a single peak is observed for the metabolites
(20) Weljie, A. M.; Newton, J.; Mercier, P.; Carlson, E.; Slupsky, C. M. Anal.
Chem. 2006, 78, 4430–4442.
(21) de Graaf, R. A.; Behar, K. L. Anal. Chem. 2003, 75, 2100–2104.
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with a single functional group (see Figures 1 and 3). The reduced
complexity of the spectra due to the absence of less interesting
chemical signals is particularly important for the analysis of lowconcentration metabolites (Figures 2 and 4). This method,
however, does not work for the analysis of lipoproteins, which
represents a major class of metabolites in blood plasma and which
have been effectively analyzed using a multivariate deconvolution
approach.22,23
An important criterion for the quantitative analysis method to
be robust is that it does not require the use of spiking standards
for each sample. To test this, we also determined the concentration
of 15N and 13C isotope tagged metabolites in plasma by
comparing the 2D peak integrals with those from the synthetic
analogues. It may be interesting to note that, as shown in
Figure 5, the values, thus, determined using both 15N and 13C
isotope tagging agree well with those determined on the basis
of spiking with synthetic analogues. Therefore, it is sufﬁcient
to obtain the integral for each synthetic analogue only once,
which can be used for the analysis of any number of samples.
Utilization of 2D HSQC experiments involving the isotopes has
the additional advantage since both the magnitude of the
coupling and the relaxation properties of the nuclear pairs (15N/
13
C and 1H) do not appreciably vary across the metabolites of
interest and, hence, provide the relative cross peak intensities
that are less sensitive to instrumental settings.
In this study, we quantiﬁed 27 metabolites with an average
CV of 2.4% for 17 metabolites and 5.6% when all the metabolites
were considered. When the results from all the four NMR
methods were combined for the same metabolites, the average
CV’s were 4.8% and 8.7%, respectively. We note that, as the
metabolite library expands, we can quantify additional metabolites
from the same and already acquired 2D data by comparison of
the peak integrals with those from the standards. Mass spectrometry (MS), another very useful method for quantitative analysis,
is highly sensitive and provides quantitative information on a larger
number of metabolites. However, MS invariably involves the
(22) Otvos, J. D.; Jeyarajah, E. J.; Bennett, D. W. Clin Chem. 1991, 37 (3),
377–386.
(23) Otvos, J. D. Clin Lab. 2002, 48, 171–180.
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combination of a separation method such as gas chromatography
or liquid chromatography for accurate analysis and often renders
the obtained results to be sensitive to the speciﬁc column and
separation parameters and especially the ionization conditions. In
addition, a standard compound is needed for each quantiﬁed
metabolite.
In conclusion, this investigation presents quantitative analysis
of over 25 plasma metabolites using 15N and 13C isotope tagging
methods. Carboxylic acids and amines represent a majority of
the metabolites in body ﬂuids, and their analysis by isotope
tagging signiﬁcantly enhances the detectable metabolic pool
for biomarker discovery applications. The combination of
improved sensitivity and resolution and the reduced time
required when compared to natural abundance heteronuclear
NMR methods are attractive for the routine and accurate
analysis of metabolites in complex biological samples. Although, the isotope tagging methods use 2D NMR experiments, each 2D experiment requires only 30 min or less (<10
min with a cryoprobe), and hence, the approach can be useful
for high throughput analysis of human plasma as well as other
biological ﬂuids. Further, combination of the isotope tagging
approach with the latest advancements in NMR technology,
such as detection using microcoil probes, for example, can
signiﬁcantly minimize the volume of bioﬂuid samples required
for routine analysis.
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ABSTRACT: Recently, the enhanced resolution and sensitivity
oﬀered by chemoselective isotope tags have enabled new and
enhanced methods for detecting hundreds of quantiﬁable
metabolites in bioﬂuids using nuclear magnetic resonance
(NMR) spectroscopy or mass spectrometry. However, the
inability to eﬀectively detect the same metabolites using both
complementary analytical techniques has hindered the correlation
of data derived from the two powerful platforms and thereby the
maximization of their combined strengths for applications such as
biomarker discovery and the identiﬁcation of unknown metabolites. With the goal of alleviating this bottleneck, we describe a
smart isotope tag, 15N-cholamine, which possesses two important properties: an NMR sensitive isotope and a permanent charge
for MS sensitivity. Using this tag, we demonstrate the detection of carboxyl group containing metabolites in both human serum
and urine. By combining the individual strengths of the 15N label and permanent charge, the smart isotope tag facilitates eﬀective
detection of the carboxyl-containing metabolome by both analytical methods. This study demonstrates a unique approach to
exploit the combined strength of MS and NMR in the ﬁeld of metabolomics.
he metabolomics ﬁeld has witnessed exponential growth
over the past decade due to its capabilities for systems
biology research and potential applications in numerous
disciplines including biomedicine, toxicology, food and
nutrition, drug development, and environmental science.1−5
Commonly used analytical techniques such as nuclear magnetic
resonance (NMR) spectroscopy and/or mass spectrometry
(MS) have evolved in response to the high demand for
resolving the complexity of biological mixtures and identifying
the large pool of quantiﬁable metabolites. However, despite
numerous advances, the biological complexity still often
outweighs the capabilities of these advanced analytical methods;
no single technique currently is capable of detecting all
metabolites in a single experiment. Each analytical method is
sensitive to certain classes of metabolites, and depending on the
nature of the metabolites of interest, generally one or
sometimes a combination of NMR or MS techniques are
used to proﬁle as many metabolites as possible and thereby
derive the biological meaning. A major hurdle of such an
approach is that the metabolite data obtained from NMR and
LC-MS or GC-MS methods for the same or similar samples are
often not directly comparable. The inability to compare and
correlate data from diﬀerent analytical techniques for the same
or similar samples is a signiﬁcant challenge that prevents
drawing meaningful conclusions from the vast amount of
metabolite data existing in the literature and exploiting the
combined strength of NMR and MS for unknown metabolite
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identiﬁcation. The main contributing factors for this bottleneck
are the limited NMR sensitivity, complex spectral signatures,
and variable MS ionization eﬃciency or suppression.
The use of chemo-selective tags provides an avenue to
improve the sensitivity of metabolite detection by both NMR
and MS methods. For example, the sensitivity of MS detection
is shown to be enhanced by three orders of magnitude or more
by tagging metabolites with chemoselective tags containing a
permanent charge.6−10 Because of the permanent charge, the
tagged metabolites are eﬀectively detected with high sensitivity
and better quantitative accuracy, irrespective of the pH or
nature of the solvents used to separate metabolites before
detection by MS. Separately, based on diﬀerential dansylation
using 12C/13C-dansyl chloride, absolute or relative quantitation
of amine and phenol containing metabolites has been achieved
with a sensitivity enhancement of three orders of magnitude.11,12 Similarly, NMR-sensitive isotope based chemoselective tags have been shown to detect many quantiﬁable
metabolites with high sensitivity and resolution by NMR.13−17
Using 15N-ethanolamine as the tag, for example, over a hundred
carboxyl-containing metabolites have been detected by 1H−15N
two-dimensional NMR with high resolution and sensitivity.13
However, while metabolites can be detected with high
Received: June 7, 2013
Accepted: August 9, 2013
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Figure 1. Schematic ﬁgure illustrating the “smart isotope tag” approach used to detect the same metabolites using NMR and MS with high
sensitivity. Tagging carboxyl-containing metabolites with 15N-cholamine enables their enhanced detection by both NMR and MS.

modiﬁcations as described below to yield the pure product.18,19
The ﬁrst step involved reacting potassium 15N-phthalimide with
(2-bromoethyl)trimethylammonium bromide in DMF to
obtain the 15N-substituted phthalimide intermediate (Scheme
1). The second step involved alkaline and acid hydrolyses of the
15
N-substituted phthalimide to yield the smart isotope tag, 15Ncholamine (Scheme 2).
Brieﬂy, for the synthesis of 15N-substituted phthalimide
(Scheme 1), (2-bromoethyl)trimethylammonium bromide (9.5
mmol, 2.35 g) was mixed with 15N-phthalimide potassium (10
mmol, 1.86 g) in a 250 mL round-bottom ﬂask and dry DMF
(100 mL) was added under nitrogen gas. The mixture was then
reﬂuxed at 100 °C with stirring for 12 h. The supernatant from
the reaction mixture was separated, and the solvent was
removed using a rotary evaporator.18 The resulting crude
residue was washed thrice using acetonitrile (5 mL each time),
twice with acetone (2 mL each time) followed by washing again
once with acetonitrile (3 mL) to obtain the pure 15Nsubstituted phthalimide. 1H NMR spectra in D2O at each
step were monitored to assess the purity of the intermediate
product. For the synthesis of 15N-cholamine, in the second
step, the 15N-substituted phthalimide (538 mg) (Scheme 1)
was dissolved in DI water (24 mL); 1 N NaOH (2.69 mL) was
added to the solution, and the mixture was left at room
temperature with stirring for 30 min to complete the alkaline
hydrolysis (Scheme 2).19 Subsequently, 12 N HCl (1.8 mL)
was added to the solution, the temperature was raised to 70 °C,
and left for 12 h with stirring to complete the acid hydrolysis
(Scheme 2).19 The solvent was then removed using a rotary
evaporator. The resulting crude residue was washed thrice with
acetonitrile (4 mL each time) followed by washing thrice with
25:75 water/acetone mixture (2 mL each time) to yield the
pure product, 15N-cholamine. 1H NMR spectra in D2O at each
step were monitored to assess the purity of the ﬁnal product.
Tagging Metabolites Using the Smart Isotope
Tag15N-Cholamine. 15N-Cholamine (5 mg, 50 μmol) was
added to 500 μL sample in an eppendorf tube, and the pH of
the mixture was adjusted to 7.0 with 1 M HCl or NaOH. A 21
mg portion of DMTMM was added to initiate the

sensitivity by both MS and NMR separately using chemoselective tags, the inability to compare and correlate the data
from the two methods is a major bottleneck in the
metabolomics ﬁeld.
The ability to more easily detect the same metabolites by
both NMR and MS methods would oﬀer new avenues to
compare data between MS and NMR platforms and to exploit
the combined strength of the complementary methods. Toward
this goal, we introduce a new “smart isotope tag” approach,
using 15N-cholamine in this case, which possesses the
characteristics of high NMR sensitivity and resolution through
its isotope enrichment and high MS sensitivity through its
permanent positive charge (see schematic Figure 1). The tag
combines the strengths of individual chemoselective tags,
demonstrated previously and separately for NMR and MS
detection,6,13 and oﬀers news avenues to exploit the combined
strength of these powerful and complementary techniques for
areas such as metabolite proﬁling and unknown metabolite
identiﬁcation.

■

EXPERIMENTAL SECTION

Chemicals and Bioﬂuids. A total of 48 carboxyl-containing
metabolite standards (Table I), (2-bromoethyl)trimethylammonium bromide, dimethylformamide (DMF),
methanol, acetonitrile, acetone, hydrochloric acid (HCl),
sodium hydroxide (NaOH) (all from Sigma-Aldrich, St.
Louis, MO), 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (Acros Organic, Pittsburgh,
PA), 15N-phthalimide potassium, and deuterium oxide (Cambridge Isotope Laboratories, Andover, MA) were used without
further puriﬁcation. Human serum samples were obtained from
Innovative Research, Inc., (Novi, MI) and urine from healthy
volunteers, in accordance with the Internal Review Board at
Purdue University. Deionized (DI) water was from in-house
Synergy Ultrapure Water System from Millipore (Billerica,
MA).
Design and Synthesis of the Smart Isotope Tag15NCholamine. Synthesis of 15N-cholamine involved a two-step
reaction and followed the Gabriel synthesis procedure with
B
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Table I. 1H and 15N-NMR Chemical Shifts for 15N-Cholamine Tagged Carboxyl-Containing Metabolites That Were Measured
with Reference to Smart Tagged Formic Acid
label
1

name
cis-aconitic acid

1

H (ppm)

15

N (ppm)

8.5
8.14
8.06
8.07
8.23
8.14
8.05
8.30
8.25
8.34
8.31
8.15
8.38
8.31

118.24
121.47
119.49
120.21
116.00
120.81
120.57
114.39
111.35
115.96
116.03
120.01
115.27
115.6

8.16
8.55
8.20
8.07
7.87
8.35
8.5
8.05
8.42
8.56
8.38
8.28
8.05

121.35
122.69
121.46
123.95
121.88
115.93
115.22
123.93
122.68
124.24
119.54
115.99
120.42

label

name

23
24

2-hydroxyisobutyric acid
DL-isocitric acid

25
26
27

isoleucine
isovaleric acid
α-ketoglutaric acid

28

lactic acid

29
30
31
32

leucine
lysine
maleic acid
malic acid

33
34
35
36

malonic acid
methionine
oxalic acid
oxaloacetic acid

37
38
39
40
41

L-phenylalanine
L-proline
propionic acid
pyroglutamic acid
Pyruvic acid

42
43

serine
succinic acid

2
3
4
5
6
7

adipic acid
DL-alanine
4-aminobenzoic acid
arginine
asparagine
aspartic acid

8
9

betaine
citric acid

10
11
12
13

cysteine
cystine
formic acid
fumaric acid

14
15

glucuronic acid
glutamic acid

16

glutamine

8.35

115.90

44

succinyl-COA

17
18

glycine
glycolic acid

19
20
21
22

hippuric acid
histidine
3-hydroxybutyric acid
4-hydroxy-L-proline

8.2
8.22
8.37
8.2
8.36
8.07
8.5
8.36

115.45
114.97
115.19
115.62
116.60
122.20
115.89
117.62

45
46
47
48

L-threonine
L-tryptophan
tyrosine
valine

1

H (ppm)
7.95
8.40
8.11
8.37
8.07
8.69
8.63
8.23
8.49
8.34
8.33
8.39
8.28
8.29
8.08
8.19
8.36
8.47
8.35
8.63
8.21
8.35
7.95
8.29
8.63
8.35
8.17
7.96
8.01
8.03
8.11
8.34
7.98
8.27
8.38

15

N (ppm)
117.51
117.15
120.77
118.19
121.92
116.34
111.84
114.18
114.45
115.74
115.88
120.39
122.83
122.15
115.14
121.44
116.08
117.13
112.67
111.40
118.85
115.58
118.85
115.88
111.39
112.72
117.63
119.16
119.64
119.17
119.67
117.79
119.37
118.05
118.20

Scheme 1. Synthesis of 15N-Substituted Phthalimide

Scheme 2. Alkaline and Acid Hydrolyses of the 15N-Substituted Phthalimide to Yield 15N-Cholamine
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Scheme 3. General Reaction for Tagging Carboxyl-Containing Metabolites with the Smart Isotope Tag 15N-Cholamine

reaction.13,20,21 The mixture was stirred at room temperature
for 4 h to complete the reaction. The general reaction for
tagging metabolites with the smart isotope tag is shown in
Scheme 3. To maintain 15N amide protonation, the pH was
adjusted to 5.0 by adding 1 M HCl or 1 M NaOH, and the
solution volume was adjusted to 580 μL by adding DI water.
Serum was deproteinized using methanol prior to metabolite
tagging and urine was used with no pretreatment.13
NMR Spectroscopy. For each sample, 580 μL was mixed
with 30 μL D2O and placed in a 5 mm NMR tube. NMR
experiments were performed on a Bruker DRX 500 MHz or
Avance III 800 spectrometer equipped with a room temperature probe or cryoprobe, respectively, suitable for 1H inverse
detection with Z-gradients at 298 K. A one pulse sequence with
or without solvent signal suppression using presaturation was
used for 1H 1D NMR experiments. The sensitivity-enhanced
1
H−15N 2D heteronuclear single quantum coherence (HSQC)
experiments employed an INEPT transfer delay of 6 ms
corresponding to the JNH of 90 Hz. Spectral widths for the 1H
and 15N dimensions were approximately 8 and 3 kHz,
respectively. Here, 128 free induction decays of 1024 data
points each were collected in the indirect (t1) dimension with 1
or 4 transients per increment. Nitrogen decoupling during the
direct acquisition (t2 dimension) was achieved with the GARP
(globally optimized alternating-phase rectangular pulses)
sequence. The resulting 2D data were zero-ﬁlled to 1024
points in the t1 dimension after forward linear prediction to 256
or 512 points. A 45° shifted sine-bell window function was
applied to both dimensions before Fourier transformation.
Chemical shifts were referenced to the 1H signal of TSP for the
1D spectra or the derivatized formic acid signal (1H 8.05 ppm;
15
N 123.93 ppm) in the HSQC spectra. Bruker Topspin
versions 3.0 or 3.1 software packages were used for NMR data
acquisition or processing.
Mass Spectrometry. LC-MS and LC-MS/MS experiments
were performed using an Agilent 1200 SL-LC system coupled
online with an Agilent 6520 Q-TOF mass spectrometer
(Agilent Technologies, Santa Clara, CA). The sample (8 μL)
was injected onto an Agilent Poroshell 120 EC-C18 column
(30 mm × 50 mm, 2.7 μm), which was heated to 50 °C. The
ﬂow rate was 0.5 mL/min. Mobile phase A was 5 mM
ammonium acetate in water, and mobile phase B was 0.1%
water in ACN. The mobile phase composition was initially kept
isocratic at 3% B for 1 min, then increased to 90% B over 4
min; after another 4 min at 90% B, the mobile phase
composition returned to 3% B. Electrospray ionization (ESI)
was used in positive mode, and the voltage was 3.5 kV. The
mass analyzer was scanned over a range of 50−1000 m/z. The
collision energy for auto LC-MS/MS experiments was ﬁxed at
10 V, targeting preselected compounds.

■

ethanolamine tag including the solubility of the tagged
metabolites in aqueous media, large one-bond J-coupling
between 1H and 15N of ∼90 Hz for eﬃcient polarization
transfer between 1H and 15N nuclei, and wide chemical shift
dispersion for diﬀerent metabolites in the resulting 2D NMR
spectra.13 In addition, and importantly, 15N-cholamine
possesses a permanent positive charge, which enables eﬃcient
positive mode detection of the same carboxyl-containing
metabolites by MS, irrespective of the pH or solvent conditions
of the eluting media, commonly used for chromatographic
separation before detection by MS.6
Synthesis of 15N-cholamine involved a two-step reaction and
followed the Gabriel synthesis procedure with suitable
modiﬁcations to yield the pure product.18,19 As seen in the
1
H NMR spectrum (Supporting Information Figure S1), the
pure intermediate compound, 15N substituted phthalimide, was
obtained after the ﬁrst step of the synthesis. Hydrolysis of this
compound yielded the 15N-cholamine in pure form as can be
ascertained from its 1 H NMR spectrum (Supporting
Information Figure S2; peaks at 3.16; 3.48; 3.64 ppm). The
accurate MS and MS/MS spectra for 15N-cholamine, shown in
Supporting Information Figure S3, help further verify the
identity and purity of the synthesized smart isotope tag (m/z =
104.120).
The compound was then used to tag 48 metabolites that
were selected for their prominence as carboxyl-containing
metabolites in bioﬂuids that represent a variety of metabolic
pathways. The 1H and 15N chemical shift data derived from the
2D NMR experiments, after tagging with 15N cholamine, are
shown in Table I. Because the 15N-cholamine and the
previously used 15N-ethanolamine diﬀer only in their terminal
group, the tagging eﬃciency, reproducibility and chemical shift
values for metabolites with 15N-cholamine tag were similar to
those obtained using the 15N-ethanolamine tag.13
Importantly, as anticipated based on the 15N-ethanolamine
tagging approach shown earlier in our laboratory,13 the 15Ncholamine tagging of metabolites in human serum provided a
rich NMR spectrum due to the large number of carboxylcontaining metabolites normally present in blood (Figure 2).
The low natural abundance of 15N (0.37%) ensures that none
of the nitrogen containing metabolites interferes with the
detection of carboxyl-metabolites through the 15N-cholamine
tag. Each peak in the spectrum corresponds to diﬀerent
metabolite from the carboxylic acid class. However, metabolites,
which contain more than one carboxyl group, provide
additional peaks depending on the number of carboxyl groups
and molecular symmetry. In addition, metabolites such as
lactate, which possess α-hydroxyl groups, show more than one
peak for the same metabolite as we described earlier using the
15
N-ethanolamine tag.13 Some of the peaks assigned based on
the chemical shift values for the standard compounds are
marked with the corresponding number shown in Table I and
Figure 2b. Similarly, tagging of metabolites in human urine with
15
N-cholamine also enabled the detection of peaks correspond-

RESULTS AND DISCUSSION

The smart isotope tag, 15N-cholamine, designed, developed,
and used in this study retains all the characteristics of the 15ND
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Figure 3. Portion of the 1H−15N HSQC spectrum of human urine
tagged with 15N-cholamine: (1) aconitic acid; (2) adipic acid; (3)
alanine; (5) arginine; (6) asparagine; (7) aspartic acid; (9) citric acid;
(12) formic acid; (15) glutamic acid; (18) glycolic acid; (19) hippuric
acid; (24) isocitric acid; (28) lactic acid; (33) malonic acid; (39)
propionic acid; (40) pyroglutamic acid; (43) succinic acid; (45)
threonine; (46) tryptophan.

The 15N-cholamine tagging of metabolites in aqueous media
enabled a sensitivity enhancement of up to 3 orders of
magnitude or more in the MS detection of carboxyl
metabolites. The derivatized metabolites could be detected
easily in positive ion mode as compared to the same
metabolites detected in negative ion mode without the tag.
For example, the sensitivity for pyruvic acid detected in positive
ion mode after 15N-cholamine tagging was enhanced by a factor
of about 1500 when compared to that detected for the same
metabolite without the 15N-cholamine tag, in negative ion
mode. Figure 4 shows typical mass spectra for formic acid and
pyruvic acid after tagging with 15N-cholamine. The enhancement in sensitivity is primarily due to the high ionization
eﬃciency imparted by the permanent positive charge of the
15
N-cholamine and is in agreement with results by Smith and
co-workers for fatty acid analysis using the heavy and light
forms of cholamine.6 In that study, reactions of metabolites
with cholamine were made in organic solution in contrast to
the aqueous media used here. The 15N-cholamine derivatized
serum samples were then analyzed by LC-MS. As anticipated,
due to the presence of the permanent positive charge, tagged
metabolites could be readily detected in positive ion mode with
high sensitivity. Sensitivity enhancement by a factor of up to
nearly 3000 could be achieved for tagged acids. The extracted
ion chromatograms for a few typical carboxylic acids detected in
serum with 15N-cholamine tag are shown in the Supporting
Information Figure S4.
One potential issue is the eﬀect on chromatographic
retention time caused by the addition of the cholamine tag.
However, separation of the tagged metabolites using HILIC
columns oﬀers an opportunity to eﬀectively separate before
detection using MS. For example, the results of separation of a
mixture of standard carboxylic and amino acids performed

Figure 2. (a) Portion of the 1H−15N HSQC spectrum of human
serum tagged with 15N-cholamine: (1) aconitic acid; (2) adipic acid;
(3) alanine; (7) aspartic acid; (8) betaine; (9) citric acid; (11) cystine;
(12) formic acid; (15) glutamic acid; (17) glycine; (20) histidine; (21)
3-hydroxybutyric acid; (24) isocitric acid; (28) lactic acid; (29)
leucine; (32) malic acid; (37) phenylalanine; (40) pyroglutamic acid;
(45) threonine; (46) tryptophan; (47) tyrosine; (48) valine. (b)
Portion of the 1H−15N HSQC spectrum of a mixture of standard
compounds at various concentrations obtained after tagging with 15Ncholamine. The peak numbers correspond to the compounds shown in
Table I.

ing to well over a hundred carboxylic acid group containing
metabolites (Figure 3). Peaks tentatively assigned based on the
values for the standard compounds are marked by their
numbers shown in Table I and Figure 2b.
E
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Figure 4. Typical LC-QTOF-MS spectra for formic acid and pyruvic acid obtained after tagging with the smart isotope tag, 15N-cholamine. The
permanent charge on the tagged metabolites enables their sensitive detection; the observed peak is from the intact tagged metabolite.

This material is available free of charge via the Internet at
http://pubs.acs.org.

using a HILIC column, without attempting to optimize
chromatography conditions, indicate that 15N-cholamine tagged
metabolites can be separated eﬀectively (Supporting Information Figure S5). More broadly, we can contemplate the use of
dual purpose smart tags for other NMR-MS combinations. For
GC-MS, the addition of a charged species will likely cause
problems related to reduced volatility; however, a diﬀerent tag,
such as 13C or even 29Si labeled silyl-type tags can be
contemplated.22 Another alternative is the use of smart tags
for capillary electrophoresis (CE) coupled to MS, which is
increasingly of interest in metabolomics.23 In fact, positively
charged derivatization agents (based on pyridinum containing
compounds) have been demonstrated for the use of metabolite
proﬁling of carboxylic acids by CE-MS.24 Thus, the potential
for the use of smart tags such as cholamine for CE-MS and
NMR is quite promising.
In conclusion, we have developed a smart isotope tag, 15Ncholamine, which possesses dual characteristics for metabolite
proﬁling in complex biological mixtures using the powerful
analytical techniques of NMR and MS. By combining the
individual strengths of the 15N label and permanent charge, the
smart isotope tag facilitates detection of carboxyl-containing
metabolome by both NMR and LC-MS techniques with high
sensitivity. Detection of the same metabolites by both NMR
and MS (Supporting Information Figure S6), eﬀectively opens
unique opportunities for identiﬁcation of unknown metabolites
and direct comparison of metabolite data from the two
powerful analytical platforms.
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